venlafaxine hydrochloride has been researched along with Depression, Involutional in 572 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (2.45) | 18.2507 |
| 2000's | 237 (41.43) | 29.6817 |
| 2010's | 271 (47.38) | 24.3611 |
| 2020's | 50 (8.74) | 2.80 |
| Authors | Studies |
|---|---|
| Carmody, T; Chin-Fatt, C; Czysz, AH; Li, Q; Mason, BL; Minhajuddin, A; Trivedi, MH | 1 |
| Aldosary, F; Blier, P; James, JS; Norris, S; Ritchie, JC; Tremblay, P | 1 |
| Amin, NS; Bardolia, C; Del Toro-Pagán, NM; Matos, A; Michaud, V; Turgeon, J | 1 |
| Chen, J; Lan, X; Lao, G; Li, G; Li, W; Ning, Y; Wang, C; Wu, K; Zhang, M; Zhang, Z; Zhou, Y | 1 |
| Hein, M; Mungo, A | 1 |
| Dao, AQ; Le, VT; Nguyen, DM; Tran, TTT; Vasseghian, Y | 1 |
| Altmann, HM; Blumberger, DM; Gebara, MA; Karp, JF; Kazan, J; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Fürst, S; Langner, C; Varelas, AI | 1 |
| Coutens, B; Guiard, BP; Rampon, C; Yrondi, A | 1 |
| Balbuena, L; Lodhi, RJ; Peters, EM | 1 |
| Kameg, BN; Wilson, R | 1 |
| Blumberger, DM; Karp, JF; Kim, HK; Lenze, E; Mulsant, BH; Reynolds, CF | 1 |
| Cai, Z; Chen, J; Fang, T; Li, Q; Lin, C; Song, X; Tian, H; Yang, L; Zhang, Q; Zhou, C; Zhuo, C | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Blanchin, M; Brunelin, J; Bulteau, S; Pere, M; Poulet, E; Sauvaget, A; Sébille, V | 1 |
| Arns, M; Enriquez-Geppert, S; Gevirtz, R; Gordon, E; Sack, AT; van der Vinne, N; van Dijk, H; Zwienenberg, L | 1 |
| Gluud, C; Hengartner, MP; Horowitz, MA; Jakobsen, JC; Juul, S; Jørgensen, CK; Kirsch, I; Moncrieff, J; Munkholm, K; Siddiqui, F | 1 |
| Li, X; Xiong, C; Xiong, Z; Yang, D; Zhou, Q | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Blumberger, DM; Daskalakis, ZJ; Jones, BDM; Le Foll, B; Sloan, ME; Tang, VM; Voineskos, D; Wang, G; Weissman, CR; Yu, D | 1 |
| Arns, M; Boutros, NN; Fallahpour, K; van der Vinne, N; van Putten, MJAM; Vollebregt, MA | 1 |
| Østergaard, SD | 1 |
| Hirakawa, H | 1 |
| Burchi, E; Fava, M | 1 |
| Bonnet, U; Knierim, U | 1 |
| Chen, C; Shan, W | 1 |
| Lenze, EJ; Miller, JP; Mulsant, BH; Nicol, G; Reynolds, CF; Saade, YM; Wetherell, JL; Yingling, M | 1 |
| Fornito, A; Goldstein-Piekarski, AN; Korgaonkar, MS; Williams, LM | 1 |
| Alexopoulos, G; Bailine, SH; Bernhardt, E; Briggs, MC; Cullum, CM; Deng, ZD; Dooley, M; Geduldig, ET; Greenberg, RM; Husain, MM; Kaliora, S; Kellner, CH; Knapp, RG; Latoussakis, V; Liebman, LS; Lisanby, SH; McCall, WV; McClintock, SM; Mueller, M; Petrides, G; Prudic, J; Rosenquist, PB; Rudorfer, MV; Sampson, S; Teklehaimanot, AA; Tobias, KG; Weiner, RD; Young, RC | 1 |
| Bi, Y; Guo, Z; He, G; He, L; Li, X; Ma, G; Niu, W; Ren, D; Shi, L; Sun, Q; Wu, X; Xu, F; Yang, F; Yu, T; Yuan, F; Yuan, R; Zhu, Y | 1 |
| Arns, M; van der Vinne, N; van Putten, MJAM; Vollebregt, MA | 1 |
| An, L; Bi, Y; Chen, Z; Dong, Z; Guo, Z; He, G; He, L; Ji, L; Li, X; Ren, D; Shi, L; Sun, X; Yang, F; Yin, L; Yu, T; Yuan, F; Yuan, R; Zhang, N | 1 |
| Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF | 1 |
| Holper, L | 1 |
| Cipriani, A; Cowen, PJ; Furukawa, TA; Leucht, S; Salanti, G | 1 |
| Albert, U; Cattaneo, A; Comandini, A; Di Dato, G; Di Loreto, G; Fagiolini, A; Ferrando, L; Herman, E; Kasper, S; Muntean, C; Olivieri, L; Pálová, E; Salvatori, E; Tongiani, S | 1 |
| Hrtanek, I; Kertys, M; Krivosova, M; Mokry, J; Ondrejka, I; Tonhajzerova, I | 1 |
| Matsuzaki, A; Sato, S; Shiratori, Y; Sodeyama, N | 1 |
| Alaiyed, S; Conant, K; Kellar, KJ; Mahajan, G; McCann, M; Rajkowska, G; Stockmeier, CA; Wu, JY | 1 |
| Brink, CB; Harvey, BH; Steyn, SF | 1 |
| Basu, S; Dass, N; Irvin, J; Keller, AS; Ng, A; Rajpurkar, P; Taylor, Z; Vale, V; Williams, LM; Yang, J | 1 |
| Husain, MM; Kellner, CH; Lisanby, SH; McCall, WV; McClintock, SM; Mueller, M; Petrides, G; Speed, MS; Østergaard, SD | 1 |
| Jain, SB; Jha, MK; Rush, AJ; South, C; Trivedi, MH | 1 |
| Alexander, R; Carboni, L; Delafont, B; Domenici, E; Ivanchenko, E; Learned, SM; Ratti, E | 1 |
| Blumberger, DM; Goldberger, KW; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Sanches, M; Thomson, L; Wathra, R | 1 |
| Birkenhäger, TK; Breteler, LMT; Janzing, JGE; Nolen, WA; van den Broek, WW; Verkes, RJ | 1 |
| Asami, Y; Boucher, M; Kato, M; Pappadopulos, E; Prieto, R; Wajsbrot, DB; Wang, X | 1 |
| Altmann, H; Blumberger, DM; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST | 1 |
| Blumberger, DM; Chen, R; Daskalakis, ZJ; Downar, J; Karp, JF; Lenze, EJ; Lissemore, JI; Mulsant, BH; Rajji, TK; Reynolds, CF | 1 |
| Gündüz, Ş; Kandeğer, A; Selvi, Y | 1 |
| Blumberger, DM; Flint, AJ; Foster, JA; Frey, BN; Hauschild, AC; Islam, F; Karp, JF; Kennedy, JL; Kennedy, SH; Lam, RW; Lenze, EJ; Maciukiewicz, M; Marshe, VS; Milev, RV; Müller, DJ; Mulsant, BH; Qin, L; Reynolds, CF; Rotzinger, S; Sibille, E; Tiwari, AK; Turecki, G | 1 |
| Malaty, J; Rousseau, C | 1 |
| Benedetti, F; Bigai, G; Branchi, I; Colombo, C; Lorenzi, C; Poletti, S; Zanardi, R | 1 |
| Boyce, P; Chen, R; Feng, L; Hu, Y; Shi, H; Wang, G; Wang, X; Xiao, L; Yang, R; Zhou, J; Zhu, X | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Alexopoulos, G; Bailine, SH; Bernhardt, E; Briggs, MC; Cullum, CM; Deng, ZD; Geduldig, ET; Greenberg, RM; Husain, MM; Kaliora, S; Kellner, CH; Knapp, RG; Latoussakis, V; Liebman, LS; Lisanby, SH; McCall, WV; McClintock, SM; Mueller, M; Petrides, G; Prudic, J; Rosenquist, PB; Rudorfer, MV; Sampson, S; Teklehaimanot, AA; Tobias, KG; Weiner, RD; Young, RC | 1 |
| Li, Y; Peng, Y; Wang, Y; Zhang, N; Zheng, J; Zhou, S | 1 |
| Cao, L; Chen, J; Cui, D; Fang, Y; Guan, Y; Hong, W; Hu, Y; Huang, J; Li, Z; Peng, D; Su, Y; Wang, Y; Wang, Z; Wu, Z; Yi, Z; Yu, S; Yuan, C; Zhang, C; Zou, Y | 1 |
| Birkenhäger, TK; Hoogendijk, WJG; Kamperman, AM; van den Broek, WW; Vermeiden, M | 1 |
| Becquemont, L; Colle, R; Corruble, E; El Asmar, K; Gressier, F; Taranu, A; Verstuyft, C | 1 |
| Civitelli, R; Dixon, D; Lenze, EJ; Mulsant, BH; Peterson, TR; Rawson, KS; Reynolds, CF | 1 |
| Asami, Y; Boucher, M; Kikuchi, T; Kornstein, S; Pappadopulos, E; Thase, ME; Tsuboi, T; Watanabe, K; Zhang, M | 1 |
| Asmar, KE; Becquemont, L; Colle, R; Corruble, E; David, D; Ferreri, F; Polosan, M; Taranu, A; Verstuyft, C | 1 |
| Bouckaert, F; Kho, KH; Kok, RM; Sienaert, P; Spaans, HP; Stek, ML; Tunney, OC; Van Den Berg, JF; Verwijk, E | 1 |
| Barbui, C; Breilmann, J; Guaiana, G; Koesters, M; Ostuzzi, G | 1 |
| Gadad, BS; Greer, TL; Jha, MK; Mayes, TL; Minhajuddin, A; Trivedi, MH | 1 |
| Aizenstein, HJ; Butters, MA; Droppa, K; Karim, HT; Karp, JF; Reynolds, CF; Tudorascu, DL | 1 |
| Dauphin, M; Geibel, B; Iosifescu, DV; Mago, R; Reynolds, J; Richards, C; Sarkis, E | 1 |
| Chen, CY; Ho, PS; Huang, CC; Huang, SY; Kuo, SC; Liang, CS; Lu, RB; Shyu, JF; Yeh, YW; Yen, CH | 1 |
| Bellivier, F; Besson, M; Calvas, F; Chevret, S; Courtet, P; Cracowski, JL; Daali, Y; Davani, S; Déglon, J; Desmeules, J; Desmidt, T; Doumy, O; El-Hage, W; Galtier, F; Haesebaert, F; Haffen, E; Heron, K; Holtzmann, J; Le Corvoisier, P; Leboyer, M; Llorca, PM; Lloret-Linares, C; Molière, F; Montange, D; Morange, S; Nieto, I; Richieri, RM; Vignaud, P; Yon, L; Yrondi, A | 1 |
| Broadhouse, K; Gordon, E; Grieve, SM; Koslow, S; Maller, JJ; Rush, AJ | 1 |
| Amsterdam, JD; Lorenzo-Luaces, L | 1 |
| Gattner, K; Górna, K; Hauser, J; Jaracz, J; Jaracz, K; Moczko, J | 1 |
| Bailine, SH; Dooley, M; Greenberg, RM; Husain, MM; Kellner, CH; Knapp, RG; Lisanby, SH; McCall, WV; McClintock, SM; McCloud, L; Mueller, M; Petrides, G; Prudic, J; Rosenquist, PB; Rudorfer, MV; Weiner, RD; Young, RC; Youssef, NA | 1 |
| Dold, M; Kasper, S; Mendlewicz, J; Montgomery, S; Olgiati, P; Serretti, A; Souery, D; Zohar, J | 1 |
| Gaedigk, A; Lalla, A; Legall, G; Montané Jaime, LK; Paul, J | 1 |
| Banach, E; Dmitrzak-Węglarz, M; Leszczyńska-Rodziewicz, A; Pawlak, J; Szczepankiewicz, A; Twarowska-Hauser, J; Zaremba, D | 1 |
| Gündüz, C; Kılınçel, O; Parmak Yener, N; Uçan Gündüz, G | 1 |
| Farsky, I; Kulhan, T; Marcincakova Husarova, V; Nosalova, G; Ondrejka, I | 1 |
| Christian, JS; Musselman, D; Ninneman, M; Ye, C; Zhang, F | 1 |
| Dronamraju, N; Greer, TL; Jha, MK; Minhajuddin, A; Trivedi, MH; Wakhlu, S | 1 |
| Becker, T; Breilmann, J; Furukawa, TA; Koesters, M | 1 |
| Martino, DJ; Szmulewicz, AG; Valerio, MP | 1 |
| Aizenstein, HJ; Andreescu, C; Butters, MA; Karim, HT; Karp, JF; Reynolds, CF; Tudorascu, D; Wang, M | 1 |
| Kavirajan, H | 1 |
| Grannemann, BD; Jha, MK; Malchow, AL; Rush, AJ; Trivedi, MH | 1 |
| Coffey, BJ; Jaffe, RJ; Juneja, NS | 1 |
| Gotlib, IH; Kircanski, K; Williams, LM | 1 |
| Aizenstein, HJ; Andreescu, C; Karim, HT; Karp, JF; Lin, C; Mizuno, A; Reynolds, CF; Wei, W | 1 |
| Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH | 1 |
| Ahmed, AT; Biernacka, JM; Bobo, WV; Frye, MA; Hall-Flavin, DK; Jenkins, G; Kung, S; Rush, AJ; Shinozaki, G; Veldic, M; Wang, L; Weinshilboum, RM | 1 |
| Braus, DF; Dreimüller, N; Elsner, S; Engel, A; Lieb, K; Roll, SC; Tadić, A; Wagner, S | 1 |
| Andersson, M; Arakawa, R; Asami, Y; Halldin, C; Hirano, Y; Lundberg, J; Nag, S; Stenkrona, P; Svensson, J; Takano, A | 1 |
| Aizenstein, H; Butters, MA; Erickson, KI; Grove, G; Gujral, S; Karp, JF; Reynolds, CF | 1 |
| Allgulander, C; Bandelow, B; Lyndon, GJ; Prieto, R; Wajsbrot, DB | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| Montgomery, SA | 1 |
| Jha, MK; Minhajuddin, A; Rush, AJ; South, C; Trivedi, MH | 1 |
| Braund, TA; Harris, AWF; Palmer, DM; Williams, LM | 1 |
| Lenze, EJ; Locke, AE; Miller, JP; Müller, DJ; Mulsant, BH; Newcomer, JW; Nicol, GE; Oughli, H; Peterson, TR; Reynolds, CF; Yingling, MD; Zhong, Y | 1 |
| Bi, Y; Guo, Z; He, G; He, L; Hu, J; Li, X; Ma, G; Niu, W; Ren, D; Sun, Q; Wang, L; Wu, X; Xu, F; Yang, F; Yu, T; Yuan, F; Yuan, R; Zhu, Y | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Gryglewski, G; Kasper, S; Komorowski, A; Kraus, C; Lamm, C; Lanzenberger, R; Paul, K; Pfabigan, DM; Seiger, R; Sladky, R; Tik, M; Vanicek, T; Windischberger, C; Woletz, M | 1 |
| Cipriani, A; Cowen, PJ; Egger, M; Furukawa, TA; Leucht, S; Salanti, G | 1 |
| Hieronymus, F | 1 |
| Machowska, M; Suwała, J; Wiela-Hojeńska, A | 1 |
| Alexander, R; Carboni, L; Delafont, B; Domenici, E; Filosi, M; Ivanchenko, E; Learned, SM; McCarthy, DJ; Ratti, E | 1 |
| Lai, CH | 1 |
| Berk, M; Bousman, CA; Byron, K; Ng, CH; Singh, AB | 2 |
| Andrade, C | 1 |
| Huang, X; Ji, JL; Li, C; Luo, YL; Wang, B | 1 |
| Dorries, KM; Dunner, DL; Gelenberg, AJ; Ninan, PT; Pedersen, R; Rothschild, AJ | 1 |
| Begley, AE; Blumberger, D; Butters, M; Dew, MA; Joel, I; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF | 1 |
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lee, IH; Lu, RB; Tsai, HC; Yang, YK | 1 |
| Geber, C; Hiemke, C; Ostad Haji, E; Schlicht, K; Tadić, A | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| Hopkins, SC; Koblan, KS; Reasner, DS | 1 |
| Angelo, LJ; Lee, KC | 1 |
| Birkenhäger, TK; Bruijn, JA; Mulder, PG; van den Broek, WW; Vermeiden, M | 1 |
| Etkin, A; Gordon, E; Grieve, SM; Harris, A; Korgaonkar, MS; Koslow, SH; Nemeroff, CB; Schatzberg, AF; Williams, LM; Wisniewski, S | 1 |
| Gibiino, S; Marsano, A; Serretti, A | 1 |
| Chen, Y; Faries, DE; Lipkovich, I; Liu, X; Obenchain, RL; Zagar, A | 1 |
| Aarya, KR; Grover, S; Sharma, A | 1 |
| Bousman, C; Byron, K; Ng, C; Peh, LH; Sarris, J; Schweitzer, I; Singh, A; Smith, DJ; Tan, CH | 1 |
| Civitelli, R; Dixon, D; Garfield, LD; Kennedy, JL; Lenze, EJ; Müller, DJ; Mulsant, BH; Reynolds, CF; Teitelbaum, SL; Todorov, AA | 1 |
| Bombardier, CH; Brooks, L; Fann, JR; Heinemann, AW; Richards, JS; Tate, DG; Temkin, NR; Warms, CA; Warren, AM; Wilson, CS | 1 |
| Eurviriyanukul, K; Maneeton, B; Maneeton, N; Srisurapanont, M | 1 |
| Bognár, Z; Gazdag, G; Vonyik, G | 1 |
| Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF | 2 |
| Miller, MC | 1 |
| Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ | 1 |
| Berk, M; Bousman, CA; Ng, CH; Singh, AB | 1 |
| de Bodinat, C; Lejoyeux, M; Matharan, S | 1 |
| Holland, PJ; Keller, MB; Kornstein, SG; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Thase, ME; Trivedi, MH | 1 |
| Bonnet, U; Khalil-Boutros, Y | 1 |
| Ellis, N; Garcia, A; Nakama, H; O'Brien, K | 1 |
| Alberti, S; Chiesa, A; Han, C; Lee, SJ; Lia, L; Pae, CU; Patkar, AA; Serretti, A | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Hough, S | 1 |
| Carmody, T; Kurian, KR; Lesser, I; Morris, D; Myers, A; Rush, AJ; Toups, M; Trivedi, MH; Warden, D; Zisook, S | 1 |
| Bellomo, G; Dalò, V; Gramaglia, C; Meola, S; Pollarolo, P; Prosperini, P; Ressico, F; Rolla, R; Torre, E; Vidali, M; Zeppegno, P | 1 |
| Bares, M; Brunovsky, M; Höschl, C; Kopecek, M; Novak, T; Sos, P; Stopkova, P | 1 |
| Choi, TK; Kim, B; Lee, MH; Lee, SH | 1 |
| Abdollahian, E; Azarpazhooh, A; Haghighi, MB; Mokhber, N; Saghebi, A; Samadi, R; Soltanifar, A | 1 |
| Groppe, S; Gründer, G; Hiemke, C; Paulzen, M; Tauber, SC; Veselinovic, T | 1 |
| Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL | 1 |
| Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S | 1 |
| Deckert, J; Hempel, S; Kopf, J; Olmes, D; Pfuhlmann, B; Proft, F; Reif, A; Riederer, P; Schmidt, B; Unterecker, S | 1 |
| Bouckaert, F; Kho, KH; Kok, RM; Sienaert, P; Spaans, HP; Stek, ML; van den Berg, JF; Verwijk, E | 1 |
| Birkenhäger, TK; Kamperman, AM; van den Broek, WW; Vermeiden, M; Vulink, ME | 1 |
| Armada, B; Blanca-Tamayo, M; Guijarro, P; Navarro-Artieda, R; Sicras-Mainar, A | 1 |
| Chen, CY; Hung, CI; Liu, CY; Wang, SJ; Yang, CH | 1 |
| Deuschle, M; Gilles, M; Gronau, W; Lederbogen, F; Paslakis, G; Schilling, C; Weber-Hamann, B | 1 |
| Bombardier, CH; Fann, JR; Forchheimer, M; Heinemann, AW; Neumann, HD; Tate, DG | 1 |
| Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR | 1 |
| Chen, CJ; Chen, CY; Ho, PS; Huang, SY; Jang, FL; Kuo, SC; Liang, CS; Lu, RB; Shyu, JF; Wan, FJ; Yeh, YW; Yen, CH | 1 |
| Barber, JK; Bombardier, CH; Brooks, L; Chiodo, AE; Fann, JR; Heinemann, AW; McCullumsmith, C; Richards, JS; Tate, DG; Temkin, NR; Wilson, CS | 1 |
| Calati, R; Dikeos, D; Gailledreau, J; Juven-Wetzler, A; Kasper, S; Mendlewicz, J; Modavi, D; Montgomery, S; Papadimitriou, GN; Papageorgiou, K; Pitchot, W; Sentissi, O; Serretti, A; Souery, D; Zohar, J | 1 |
| Etkin, A; Patenaude, B; Rekshan, W; Rush, AJ; Schatzberg, AF; Song, YJ; Usherwood, T; Williams, LM | 1 |
| Arnow, BA; Boyce, PM; Day, CV; DeBattista, C; Etkin, A; Harris, AW; John Rush, A; Rekshan, W; Schatzberg, AF; Williams, LM | 1 |
| Bombardier, CH; Brooks, L; Fann, JR; Heinemann, AW; McCullumsmith, CB; Richards, JS; Tate, DG; Temkin, NR; Warms, C; Warren, AM; Wilson, CS | 1 |
| Berm, EJ; Boshuisen, M; Breuning, L; Brouwers, JR; Dhondt, T; Hak, E; Jansen, PA; Kok, RM; Maring, JG; Mulder, H; Postma, M; Risselada, AJ; van Marum, R; Venema, H; Vleugel, L; Voshaar, RC; Wilffert, B | 1 |
| Brunnauer, A; Buschert, V; Distler, G; Fric, M; Laux, G; Sander, K; Segmiller, F; Zwanzger, P | 1 |
| Filippov, G; Gislum, M; Montgomery, S; Wang, G | 1 |
| Arnow, BA; Blasey, C; Etkin, A; Kulkarni, J; Luther, JF; Palmer, DM; Rekshan, W; Rush, AJ; Schatzberg, AF; Williams, LM | 1 |
| DeBattista, C; Etkin, A; Lazzeroni, LC; Murphy, GM; Schatzberg, AF; Williams, LM | 1 |
| Eagles, S; Etkin, A; Goldstein-Piekarski, A; Grieve, SM; Harris, AW; Korgaonkar, MS; Paton, R; Song, YC; Usherwood, T; Williams, LM | 1 |
| Chen, J; Gong, W; Li, Z; Mu, J; Shao, W; Wu, Q; Xie, P; Xu, F; Yang, D; Yang, J; Yang, Y; Zhang, J | 1 |
| Etkin, A; Grieve, SM; Gyurak, A; Korgaonkar, MS; Patenaude, B; Williams, LM | 1 |
| Ivanets, NN; Iziumina, TA; Kinkulkina, MA; Tikhonova, YG | 1 |
| Emilsson, JF; Eriksson, E; Hieronymus, F; Nilsson, S | 1 |
| Arns, M; DeBattista, C; deBeuss, R; Etkin, A; Fitzgerald, PB; Gordon, E; Harris, A; Hegerl, U; Palmer, DM; Williams, LM | 1 |
| del Río-Casanova, L; Díaz-Llenderrozas, F; Portela, B | 1 |
| Bergink, V; Birkenhager, TK; Carvalho, LA; Drexhage, HA; Grosse, L; Hoogendijk, WJ; Kushner, SA | 1 |
| Miskovic, M | 1 |
| Aydin, A; Boysan, M; Güzel Özdemir, P; Selvi, Y; Smolensky, MH; Yilmaz, E | 1 |
| Beer, AJ; Riepe, MW; Vonend, C; Walther, B | 1 |
| Bavle, A | 1 |
| Begley, A; Blumberger, DM; Butters, MA; Dew, MA; Hall, CA; Lenze, EJ; Mulsant, B; Reynolds, CF; Simon, KM; Stack, JA | 1 |
| Arns, M; Debattista, C; Fallahpour, K; Fitzgerald, P; Gordon, E; Jongsma, ML; Kenemans, L; Kessels, RP; van Dinteren, R; Williams, LM | 1 |
| Aizenstein, H; Anderson, SJ; Butters, MA; Dew, MA; Lenze, EJ; Lotrich, FE; Mulsant, BH; Reynolds, CF; Smagula, SF | 1 |
| Damkier, P; Ennis, ZN; Lassen, D | 1 |
| Balestri, M; Calati, R; Kasper, S; Kautzky, A; Mendlewicz, J; Montgomery, S; Serretti, A; Souery, D; Zohar, J | 1 |
| Asami, Y; Higuchi, T; Imaeda, T; Itamura, R; Kamijima, K; Kuribayashi, K; Nakagome, K | 1 |
| Brignone, M; Campbell, R; Cho, SJ; Choi, SE; Francois, C; Jeon, HJ; Jung, R; Milea, D | 1 |
| Basi, C; D'Agostino, A; Demartini, B; Gambini, O | 1 |
| Brody, BD; Chaudhry, SK; Dubin, M; Meltzer, EC; Penzner, JB | 1 |
| Messer, T | 1 |
| Groot, PC; Wichers, M | 1 |
| Diaz, SH; Dunklee, L; Escalona, R; Fawcett, J; Romo, P; Rush, AJ; Vukelich, J; Yarns, BC | 1 |
| Bombardier, CH; Fann, JR; Forchheimer, M; Heinemann, AW; Neumann, HD; Richardson, EJ; Williams, RT | 1 |
| Baldwin, DS; Chrones, L; Florea, I; Nielsen, R; Nomikos, GG; Palo, W; Reines, E | 1 |
| Citrome, L | 1 |
| Aizenstein, HJ; Anderson, SJ; Blumberger, D; Butters, MA; Dew, MA; Diniz, BS; Kaneriya, SH; Karp, JF; Lenze, EJ; Lotrich, F; Mulsant, BH; Reynolds, CF; Robbins-Welty, GA; Smagula, SF | 1 |
| Kumbhare, D; Sabharwal, S | 1 |
| Forchheimer, M; Heinemann, AW; McCullumsmith, C; Warren, AM; Wilson, CS | 1 |
| Gordon, E; Grieve, SM; Korgaonkar, MS; Rush, AJ; Williams, LM | 1 |
| Blumberger, DM; Cristancho, P; Dixon, D; Lenze, EJ; Mulsant, BH; O'Connor, B; Reynolds, CF | 1 |
| Bai, SJ; Huang, T; Lan, XH; Qin, B; Xie, P; Xu, Y | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR | 1 |
| Dong, Y; Du, J; Fan, J; Gu, X; Mackie, MA; Spagna, A; Tian, Y; Wang, K | 1 |
| Anderson, SJ; Blumberger, DM; Butters, MA; Dew, MA; Diniz, BS; Karp, JF; Lenze, EJ; Lotrich, FE; Mulsant, BH; Reynolds, CF; Smagula, SF; Wallace, ML | 1 |
| Bradley, R; Dillon, JE; Khalid, Z; Osuagwu, FC; Roy, N; Shah, B | 1 |
| Brawman-Mintzer, O; Dauphin, M; Gao, J; Geibel, B; Madhoo, M; McIntyre, RS; Richards, C; Sambunaris, A; Weisler, R | 1 |
| Brooks, MM; Luther, JF; Potter, MA; Roberts, MS; Singh, A; Voorhees, RE; Wisniewski, SR | 1 |
| Blumberger, DM; Hsu, JH; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Reynolds, CF; Roose, SP | 1 |
| Blumberger, D; Butters, M; Buysse, DJ; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, B; Reynolds, CF; Stahl, ST; Waterman, L | 1 |
| Aalto-Setälä, M; Brignone, M; Campbell, R; Cure, S; Danchenko, N; Diamand, F; Hallinen, T; Kolasa, K; Koponen, H; Soini, E | 1 |
| Asami, Y; Boucher, M; Dorries, K; Pappadopulos, E; Thase, M; Wajsbrot, D | 1 |
| Brunelin, J; Haesebaert, F; Moirand, R; Poulet, E; Schott-Pethelaz, AM | 1 |
| Blumberger, DM; Karp, JF; Kennedy, JL; Lenze, EJ; Maciukiewicz, M; Marshe, VS; Müller, DJ; Mulsant, BH; Rej, S; Reynolds, CF; Sibille, E; Tiwari, AK | 1 |
| Celikel, FC; Cumurcu, BE; Guzey, IC; Hasbek, E; Kan, D; Ozbey, G; Percin, F; Uluoglu, C; Yucel, B | 1 |
| Chekroud, AM; Gueorguieva, R; Krumholz, HM; Krystal, JH; McCarthy, G; Trivedi, MH | 1 |
| Albani, D; Calabrò, M; Calati, R; Crisafulli, C; Fabbri, C; Forloni, G; Juven-Wetzler, A; Kasper, S; Martines, R; Mendlewicz, J; Montgomery, S; Serretti, A; Souery, D; Zohar, J | 1 |
| Bonaccorso, S; Girardi, P; Matrisciano, F; Nicoletti, F; Panaccione, I; Ricciardi, A; Ruberto, A; Scaccianoce, S; Shelton, RC; Tatarelli, R; Wang, L | 1 |
| Gourion, D | 1 |
| Anderson, IM; Haddad, PM; Tint, A | 1 |
| Khandker, RK; Kruzikas, DT; McLaughlin, TP | 1 |
| de Abajo, FJ; García-Rodríguez, LA | 1 |
| Chrzanowski, W; Gee, M; Hewett, K; Krishen, A; Leary, MO; Milanova, V; Millen, L; Modell, J; Savela, A; Schmitz, M | 1 |
| Harrison, C; Lane, C; Steen, N; Vanoli, A; Young, A | 1 |
| Katona, C | 1 |
| Davis, LL; Fava, M; Luther, JF; Nierenberg, AA; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Kim, YK; Lee, HY | 1 |
| Jureidini, J; Mintzes, B | 1 |
| Amsterdam, JD; Shults, J | 1 |
| Ehret, MJ; Grgas, M; Sopko, MA | 1 |
| Dekker, J; Peen, J; Schoevers, RA; van Aalst, G; Van, HL | 1 |
| Boyer, P; Brisard, C; Ganguly, R; Germain, JM; Lepola, U; Montgomery, S; Padmanabhan, SK; Tourian, KA | 1 |
| Millet, B | 1 |
| Buitelaar, JK; Roobol, TH | 1 |
| Kaplan, P; Kora, K | 1 |
| Deuschle, M; Frankhauser, P; Gilles, M; Kopf, D; Lederbogen, F; Onken, V; Schilling, C; Weber-Hamann, B | 1 |
| Flockhart, DA; Hayes, DF; Henry, NL; Riba, M; Stearns, V | 1 |
| Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K | 1 |
| Cunha, FT; Ladeira, RB; Nicolato, R; Salgado, JV; Teixeira, AL | 1 |
| Bunchapattanasakda, C; Kongsakon, R | 1 |
| Ahmed, S; Dunlop, BW; Friedman, ES; Keller, M; Kocsis, JH; Kornstein, SG; Li, T; Ninan, PT; Pedersen, R; Thase, M; Yan, B | 1 |
| Chen, CH; Lu, ML | 1 |
| Heeren, TJ; Kok, RM; Nolen, WA | 2 |
| Cook, IA; Hunter, AM; Leuchter, AF; Ravikumar, S | 1 |
| Bahk, WM; Chae, JH; Jun, TY; Jung, YE; Seo, HJ; Woo, YS | 1 |
| Bauer, M; Freemantle, N; Moeller, HJ; Tharmanathan, P; Volz, HP | 1 |
| Kyomen, HH; Whitfield, TH | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J | 1 |
| Entsuah, R; Nemeroff, CB; Sheehan, DV; Thase, ME | 1 |
| Arocha, L; Fazzino, F; Lima, L; Mata, S; Morles, M; Obregón, F; Rojas, A | 1 |
| Hung, CI; Liu, CY; Wang, SJ | 1 |
| Burslem, K; Greenstreet, L; Knight, C; Lenox-Smith, A | 1 |
| Bares, M; Brunovsky, M; Höschl, C; Kopecek, M; Kozeny, J; Novak, T; Sos, P; Stopkova, P | 1 |
| Bauer, M; Jiang, Q; Loeschmann, PA; Moeller, HJ; Ninan, PT; Schmitt, AB; Volz, HP | 1 |
| Caykoylu, A; Ekinci, O; Kuloglu, M | 1 |
| Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB | 1 |
| Brown, L; Eliasziw, M; Lavorato, DH; McLaren, L; Patten, SB; Williams, JV | 1 |
| Heeren, TJ; Kok, RM; Nolen, WA; van Baarsen, C | 1 |
| Bukh, JD; Dam, H; Jørgensen, MB; Plenge, P | 1 |
| Spadone, C | 1 |
| Dekker, J; Hendriksen, M; Koelen, J; Kool, S; Peen, J; Schoevers, R; van Aalst, G; Van, HL | 1 |
| Avissar, S; Golan, M; Matuzany-Ruban, A; Miroshnik, N; Schreiber, G | 1 |
| Ash, P; Jacob, MK | 1 |
| Germain, JM; Guico-Pabia, C; Jiang, Q; Kornstein, SG; Ninan, PT; Thase, ME | 1 |
| Clayton, AH; Guico-Pabia, C; Kornstein, SG; Rosas, G; Tourian, KA | 1 |
| Hassan, M; Marcus, SC; Olfson, M | 1 |
| Arnow, BA; Barkin, JL; Dowling, F; Klein, DN; Kocsis, JH; Leon, AC; Manber, R; Rothbaum, BO; Trivedi, MH; Wisniewski, SR | 1 |
| Bieling, PJ; Kennedy, SH; Konarski, JZ; Lau, MA; Mayberg, HS; McIntyre, RS; Segal, ZV | 2 |
| Amsterdam, J; Hilbe, JM; Kim, H; Shults, J; Sun, W; Ten-Have, T; Tu, X | 1 |
| Becker, T; Koesters, M; Weinmann, S | 2 |
| Kodaka, F; Koga, M; Miyata, H; Nakayama, K | 1 |
| Alpert, JE; Denninger, JW; Devlin, P; Fava, M; Greenwald, S; Iosifescu, DV; Mischoulon, D | 1 |
| Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF; Muthén, BO | 1 |
| Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV | 1 |
| Bakish, D | 1 |
| Andersen, HF; Kornstein, SG; Larsson, S; Li, D; Mao, Y; Papakostas, GI | 1 |
| Akkaya, C; Cangur, S; Eker, SS; Kirli, S; Sarandol, A | 1 |
| Amsterdam, JD; Shults, J; Wang, G | 1 |
| Chung, SK; Hong, JP; Kang, EH; Kim, EJ; Kim, S; Lee, IS; Lee, SY; Oh, KS; Park, JE; Woo, JM; Yu, BH | 1 |
| Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C | 1 |
| Dunlop, BW; Dunner, DL; Friedman, ES; Gelenberg, A; Goldstein, C; Holland, P; Keller, MB; Kocsis, JH; Kornstein, SG; Pedersen, R; Rothschild, AJ; Shelton, R; Thase, ME; Trivedi, MH; Zajecka, JM | 1 |
| Brent, DA | 1 |
| Başterzi, AD; Buturak, V; Cimen, B; Eskandari, G; Taşdelen, B; Tot Acar, S; Yazici, A; Yazici, K | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, G; Goldstein, BI; Mayes, T; Onorato, M; Ryan, N; Shamseddeen, W; Spirito, A; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Birkenhäger, TK; Boks, MP; Breteler, LM; Bruijn, JA; Burger, H; Janzing, JG; Nolen, WA; van den Broek, WW; van der Loos, ML; Verkes, RJ; Wijkstra, J | 1 |
| Fava, M; Gaynes, BN; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Laje, G; McMahon, FJ; Perlis, RH; Rush, AJ | 1 |
| Baune, BT; Caliskan, S; Todder, D | 2 |
| Grønli, O; Olstad, R; Stensland, GØ; Wynn, R | 1 |
| Devane, CL; Fareed, J; Halaris, A; Hoppensteadt, D; Iqbal, O; Piletz, JE; Sinacore, J; Zhu, H | 1 |
| Evoniuk, G; Gee, MD; Hewett, K; Krishen, A; Le Clus, A; Modell, JG; Wunderlich, HP | 1 |
| Bonelli, RM; Holl, AK; Holl, EM; Painold, A; Wilkinson, L | 1 |
| Gourion, D; Montagne, A; Olié, JP; Poirier, MF; Rostin, M | 1 |
| Bergeron, R; Blier, P; Hébert, C; Laberge, L; Tremblay, P; Ward, HE | 1 |
| Angermeier, T; Deuschle, M; Frankhauser, P; Gilles, M; Kopf, D; Lederbogen, F; Onken, V; Schilling, C; Weber-Hamann, B; Westphal, S | 1 |
| Amara, G; Ben Hadj Ali, B; Ben Nasr, S; Saada, W | 1 |
| Rush, AJ | 2 |
| Dunlop, BW; Friedman, ES; Keller, M; Kornstein, SG; Li, T; Ninan, P; Pedersen, R; Rothschild, AJ | 1 |
| Bitter, I; Karamustafalioglu, O; Koponen, H; Mohr, P; Sartorius, N; Seifritz, E; Svestka, J | 1 |
| Despiégel, N; Lam, RW; Lönn, SL | 1 |
| Deuschle, M; Frankhauser, P; Gilles, M; Kopf, D; Lederbogen, F; Onken, V; Scharnholz, B; Schilling, C; Weber-Hamann, B | 1 |
| Preskorn, SH | 1 |
| Dunner, DL; Friedman, ES; Gelenberg, A; Keller, MB; Kocsis, JH; Kornstein, SG; Rothschild, AJ; Shelton, RC; Thase, ME; Trivedi, MH; Zajecka, JM | 1 |
| Caratan, S; Mihanović, M; Presecki, P; Silić, A; Vuina, AL | 1 |
| Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Nierenberg, AA; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
| Heeren, T; Kok, R; Nolen, W | 1 |
| Deuschle, M; Gilles, M; Paslakis, G | 1 |
| Choi, TK; Kim, SJ; Lee, E; Lee, HS; Lee, SH; Seok, JH | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lee, IH; Lee, SY; Lu, RB; Yang, YK | 1 |
| Danchenko, N; Despiegel, N; Maman, K; Marteau, F; Nordström, G | 1 |
| Gelenberg, A; Keller, M; Kocsis, JH; Kornstein, SG; Li, T; Ninan, P; Pedersen, R; Thase, ME; Trivedi, MH | 1 |
| Becker, T; Grouven, U; Kaiser, T; Kerekes, MF; Koesters, M; Kreis, J; Kromp, M; Schueler, YB; Weinmann, S; Wieseler, B | 1 |
| Plesnicar, BK | 1 |
| Agius, M; Bugler, R; Tavormina, G; Zaman, R | 1 |
| Bokde, AL; Brückmann, H; Frodl, T; Hampel, H; Koutsouleris, N; Linn, J; Meisenzahl, E; Möller, HJ; Scheuerecker, J; Schoepf, V; Wiesmann, M | 1 |
| Raj, YP | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lu, RB; Wang, HC; Yang, YK; Yeh, TL | 1 |
| Blanca-Tamayo, M; Gimeno-de la Fuente, V; Navarro-Artieda, R; Salvatella-Pasant, J; Sicras-Mainar, A | 1 |
| Lobello, K; Musgnung, J; Ninan, PT; Pedersen, R; Reddy, S | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF | 2 |
| Chang, JP; Su, KP; Wu, CC | 1 |
| Chaney, A; Frodl, T; Lisiecka, D; Meisenzahl, E; Moeller, HJ; Scheuerecker, J; Schoepf, V; Whitty, P; Wiesmann, M | 1 |
| Haskett, R; Isenberg, K; Kimball, J; Lasater, B; McCall, WV; Prudic, J; Rosenquist, PB; Sackeim, HA | 1 |
| Cooper, NJ; Gordon, E; Koslow, SH; Nemeroff, CB; Rush, AJ; Schatzberg, AF; Williams, LM; Wisniewski, SR | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; DeBar, L; Dickerson, J; Emslie, G; Iyengar, S; Keller, MB; Kennard, B; Lynch, F; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Robinson, RL; Swindle, RW; Ye, W; Zhao, Y | 1 |
| Angermeier, T; Deuschle, M; Gilles, M; Hummel, J; Kopf, D; Lederbogen, F; Luley, C; Weber-Hamann, B; Westphal, S | 1 |
| Liang, CS; Yang, FW | 1 |
| Ancock, B; Cuevas, C; Lung, D; Zaid, U | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Dickerson, JF; Emslie, G; Iyengar, S; Keller, MB; Kennard, B; Lynch, FL; Mayes, T; McCracken, JT; Onorato, M; Porta, G; Ryan, ND; Spirito, A; Strober, M; Suddath, RL; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP | 1 |
| Rakun, R; Ružić, K; Sabljić, V | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; Emslie, G; Goldstein, T; Keller, MB; Mayes, T; Perel, J; Porta, G; Ryan, ND; Sakolsky, D; Wagner, KD; Woldu, H | 1 |
| Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Cook, IA; Hunter, AM; Korb, AS; Leuchter, AF | 1 |
| Liu, X; Mullins, CD; Wang, J | 1 |
| Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Fiedler, JL; Fritsch, R; Jara, P; Rojas, PS; Rojas, RA | 1 |
| Brooks, WB | 1 |
| Barak, Y; Baruch, Y; Swartz, M | 1 |
| Bahk, WM; Jun, TY; Jung, YE; Kim, KS | 1 |
| Alvarez, E; Artigas, F; Dragheim, M; Loft, H; Perez, V | 1 |
| Guico-Pabia, CJ; Jiang, Q; Ninan, PT; Thase, ME | 1 |
| Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Light, SN; Peterson, MJ | 2 |
| Garakani, A; Gorman, JM; Martinez, JM; Yehuda, R | 2 |
| de Silva, VA; Hanwella, R | 1 |
| Alexander, R; Archer, G; Evoniuk, G; Graff, O; Krishnan, KR; Lavergne, A; Learned, S; Moate, R; Modell, JG; Ratti, E; Roychowdhury, S; Zamuner, S | 1 |
| Fava, M; Kallenberg, G; Lebowitz, B; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S | 1 |
| Frölich, L; Hausner, L; Janke, C; Kranaster, L; Sartorius, A | 1 |
| Barber, JP; Barrett, MS; Gallop, R; Rickels, K; Rynn, MA | 1 |
| Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Miller, WC; Stürmer, T | 1 |
| Hung, CI; Liu, CY; Wang, SJ; Yang, CH | 1 |
| Asarnow, JR; Brent, D; Clarke, G; Emslie, GJ; Iyengar, S; Keller, M; Onorato, M; Porta, G; Ritz, L; Ryan, N; Vitiello, B; Wagner, KD; Zelanzny, J | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, GJ; Keller, MB; Porta, G; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Brown, CH; Davis, J; Gibbons, RD; Hur, K; Mann, JJ | 1 |
| Kocsis, JH | 1 |
| Barbini, B; Benedetti, F; Colombo, C; Dallaspezia, S; Fulgosi, MC; Gavinelli, C; Smeraldi, E | 1 |
| Brown, CH; Davis, JM; Gibbons, RD; Hur, K; Mann, JJ | 1 |
| Weder, N | 1 |
| Rubin, DH | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Dickerson, JF; Dietz, LJ; Emslie, G; Keller, M; Kennard, B; Lynch, FL; Mayes, T; McMakin, DL; Olino, TM; Porta, G; Ryan, ND; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Bech, P; Lunde, M; Martiny, K; Plenge, P | 1 |
| Bao, W; Dunlop, BW; Holland, P; Keller, MB; Ninan, PT | 1 |
| Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S | 1 |
| Al-Najjar, T; Ali, BA; Nazer, LH; Shankar, G | 1 |
| Chiang, KT; Ho, PS; Liang, CS; Su, HC | 1 |
| Chen, J; Cui, D; Fang, Y; Hong, W; Li, Z; Qi, D; Wang, Z; Yi, Z; Yu, S; Yuan, C; Zhang, C | 1 |
| Fava, M; Haley, CL; Kurian, BT; Morris, DW; Nierenberg, AA; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Chang, JS; Ha, K; Ha, TH; Her, JY; Park, T; Yi, SH; Yoo, CS; Yoon, IY | 1 |
| De Berardis, D; Di Giannantonio, M; Di Iorio, G; Di Nicola, M; Gambi, F; Janiri, L; Martinotti, G; Onofrj, M; Sepede, G | 1 |
| Deuschle, M; Gilles, M; Gronau, W; Kopf, D; Lecei, O; Lederbogen, F; Roth, HJ; Scharnholz, B; Schilling, C; Terhardt, J; Weber-Hamann, B | 1 |
| Canny, LM; Coleman, KA; Meaney, JV; Palmer, TL; Radalj, LM; Xavier, VY | 1 |
| Leelahanaj, T | 1 |
| Deuschle, M; Gilles, M; Hellweg, R; Lang, UE; Lederbogen, F; Scharnholz, B | 1 |
| Auchincloss, EL; Occhiogrosso, M | 1 |
| Fava, M; Perlis, RH; Perroud, N; Uher, R | 1 |
| Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S | 1 |
| Cruz, R; Dennison, EA; Raidoo, BM; Raidoo, D | 1 |
| Adams, J; Graves, N; Solomon, D | 1 |
| Agosti, V; Bisaga, A; Brooks, DJ; Carpenter, KM; Levin, FR; Mariani, J; Nunes, EV; Pavlicova, M; Sullivan, MA | 1 |
| Brus, O; Carlborg, A; Engström, I; Ljung, T; Nordenskjöld, A; von Knorring, L | 1 |
| Civitelli, R; Dixon, D; Doré, P; Garfield, LD; Lenze, EJ; Mulsant, BH; Reynolds, CF; Shea, ML; Teitelbaum, S | 1 |
| Kaplan, EM | 1 |
| Cantillon, M; Davidson, JR; Hackett, D; Haudiquet, V; Meoni, P | 1 |
| Berigan, T | 1 |
| Frare, F; Perugi, G; Ruffolo, G; Toni, C; Torti, C | 1 |
| Arias, F; Carrasco, JL; Chamorro, L; Díaz-Marsá, M; Ferrando, L; Ibáñez, A; Jordá, L; Martín-Ballesteros, E; Martín-Carrasco, M; Montes, JM; Padín, J; Sáiz-Ruiz, J | 1 |
| Thase, ME; Trivedi, M | 1 |
| Artigas, F; Nutt, DJ; Shelton, R | 1 |
| Ansseau, M; Charlier, C; Pinto, E; Plomteux, G | 1 |
| Anderle, MJ; Davidson, RJ; Irwin, W; Kalin, NH | 1 |
| Haack, M; Hinze-Selch, D; Koethe, D; Kraus, T; Pollmächer, T; Schuld, A | 1 |
| Gastó, C; Marcos, T; Navarro, V; Portella, MJ; Rodamilans, M; Torra, M | 1 |
| Casciano, R | 1 |
| Burrows, GD; Gupta, RK; Tiller, JW | 1 |
| Malek-Ahmadi, P | 1 |
| Dierkes, W; Huppertz-Helmhold, S; Sauer, H | 1 |
| Hwang, JP; Tsai, SJ; Yang, CH | 1 |
| Fountoulakis, KN; Iacovides, A; St Kaprinis, G | 1 |
| Entsuah, R; Hackett, D; Kunz, NR; Montgomery, SA; Rudolph, RL | 1 |
| Albano, D; Grothe, DR; Scheckner, B | 1 |
| Alamo, C; López-Muñoz, F; Rubio, G; San, L | 1 |
| Baboolal, NS | 1 |
| Azen, SP; Chou, CP; James Gauderman, W; Leuchter, AF; Marie-Mitchell, A | 1 |
| Carnes, CA; Pickworth, KK; Raman, SV; Votolato, NA | 1 |
| Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
| Pavlovic, ZM | 1 |
| Buchkremer, G; Laske, C; Leyhe, T; Wormstall, H | 1 |
| Courtney, DB | 1 |
| Goodman, M; Grossman, R; Mitropoulou, V; New, A; Reynolds, D; Schmeidler, J; Siever, LJ; Silverman, J | 1 |
| Chamberlain, JC; Jones, L; Weiss, NT | 1 |
| Allard, P; Behnke, K; Gram, L; Hanson, M; Søgaard, J; Timdahl, K | 1 |
| Alpert, JE; Bottiglieri, T; Burns, A; Fava, M; Mahal, Y; Mischoulon, D; Nierenberg, AA; Papakostas, G; Petersen, T; Worthington, JJ | 1 |
| Albano, D; Zajecka, JM | 1 |
| Shelton, CI | 1 |
| Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM | 1 |
| Aydemir, O; Deveci, A; Taneli, F | 1 |
| Lange, CL | 1 |
| Carey, TS; Gartlehner, G; Gaynes, BN; Hansen, RA; Lohr, KN; Randolph, LC | 1 |
| Fernandez, JL; Francois, C; Montgomery, S | 1 |
| Annemans, L; Demyttenaere, K; Hemels, ME; Hudry, J | 1 |
| Addington, S; Dichter, GS; Freid, CM; Shelton, RC; Tomarken, AJ | 1 |
| Hauser, P; Hisley, KC; Lefkowitz, DM; Marano, C; Obuchowski, A; Regenold, WT | 1 |
| Almási, J; Rihmer, Z | 1 |
| Kennedy, SH; Lam, RW | 1 |
| Benazzi, F | 1 |
| Berger, M; Feige, B; Nissen, C; Nofzinger, E; Riemann, D; Voderholzer, U | 1 |
| Bastiaens, L | 1 |
| Entsuah, R; Padmanabhan, SK; Shelton, C; Vinall, PE | 1 |
| Posternak, MA; Zimmerman, M | 1 |
| Bannan, N | 1 |
| Devarajan, S; Dursun, SM | 1 |
| Einarson, TR; van Baardewijk, M; Vis, PM | 2 |
| Briley, M; Grady, MM; Moret, C; Stahl, SM | 1 |
| Cantillon, M; Entsuah, R; Kornstein, SG; Thase, ME | 1 |
| Burt, T; D'Souza, RF; George, T; Hopwood, M; Lam, W; Martin, AJ; Sir, A; Uguz, S; Vahip, S | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Brørs, O; Melien, Ø; Myhr, K; Skaali, T | 1 |
| Baldwin, DS; Lader, M; Montgomery, SA; Nil, R | 1 |
| Giordani, S; Lucca, A; Magri, L; Rossini, D; Smeraldi, E; Zanardi, R | 1 |
| Baker, RA; Benkert, O; Heinrich, C; Heukels, A; Kohnen, R; Philipp, M; Schutte, AJ; Simmons, JH; Szegedi, A; van der Vegte-Senden, M | 1 |
| Ballon, JS; Schulman, MC | 1 |
| Benattia, I; Graepel, J; Kroenke, K; Messina, N; Musgnung, J | 1 |
| Liau, CH; Shen, WW; Su, KP | 1 |
| Al-Adwani, A | 1 |
| Millan, MJ | 1 |
| Biggs, MM; Fava, M; Luther, JF; Niederehe, G; Nierenberg, AA; Ritz, L; Rush, AJ; Shores-Wilson, K; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Andersen, HF; Kennedy, SH; Lam, RW | 1 |
| Roose, S; Schatzberg, A | 1 |
| Begley, AE; Kirshne, MA; Mulsant, BH; Pollock, BG; Reynolds, CF; Romkes, M; Whyte, EM | 1 |
| Sicot, R | 1 |
| Keltner, NL; Lee, SI | 1 |
| Blier, P; de Montigny, C; Debonnel, G; Hébert, C; Lavoie, N; Saint-André, E | 1 |
| Khan, A; Shelton, RC; Thase, ME | 1 |
| Briggs, SD; Case, M; Corya, SA; Sanger, TM; Tollefson, G; Williamson, D | 1 |
| Hsiao, CC | 1 |
| Anghelescu, I; Luborzewski, A; Regen, F; Schindler, F | 1 |
| Kim, YK; Lee, KM | 1 |
| Akgoz, S; Akkaya, C; Kirli, S; Sarandol, A; Saygin Eker, S; Yazicioglu, B | 1 |
| Akgoz, S; Akkaya, C; Eker, SS; Kirli, S; Sivrioglu, EY | 1 |
| Eckert, L; Lançon, C | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF; Morgan, ML | 1 |
| Andersen, HF; Montgomery, SA | 1 |
| Abad-Santos, F; Adan-Manes, J; Ayuso-Mateos, JL; López-Rodríguez, R; Novalbos, J | 1 |
| Begley, AE; Johnson, EM; Mulsant, BH; Pollock, BG; Reynolds, CF; Weber, E; Whyte, E | 1 |
| Valenstein, M | 1 |
| Biggs, MM; Davis, L; Fava, M; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Clayton, AH; Haight, BR; Johnston, JA; Modell, JG; Thase, ME; Thompson, AH | 1 |
| Fotiou, F; Fountoulakis, KN; Gerasimou, G; Grammatikos, P; Iacovides, A; Kaprinis, G; Karamouzis, M | 1 |
| Christodoulou, C; Douzenis, A; Lykouras, L; Michopoulos, I | 1 |
| Eckert, L; Falissard, B | 1 |
| Kornstein, SG | 1 |
| Gendron, A; McIntyre, A | 1 |
| Bremner, JD; Charney, DS; Vermetten, E; Vythilingam, M | 1 |
| Dunner, DL; Haman, KL; Hirschfeld, RM; Kiev, A; Lydiard, RB; Rapaport, MH; Shelton, RC; Smith, WT; Zajecka, JM | 1 |
| Berman, SA; Packer, S | 1 |
| Barbui, C; Cipriani, A; Geddes, JR | 1 |
| Artiges, E; Bragulat, V; Frouin, V; Martinot, JL; Paillère-Martinot, ML; Poline, JB | 1 |
| Emslie, GJ; Kunz, NR; Yeung, PP | 1 |
| de Leeuw, FE; Heeren, TJ; Hulshoff Pol, HE; Janssen, J; Kahn, RS; Kok, RM; Lampe, IK; Schnack, HG | 1 |
| Archambaud, F; Buhl, C; Chouinard, G; Corruble, E; Hardy, P; Prigent, A; Schuster, JP | 1 |
| Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R | 1 |
| Fernandez, JL; Llorca, PM | 1 |
| Alam, F; Ashim, S; Bennett, D; Mbaya, P | 1 |
| Emslie, GJ; Findling, RL; Kunz, NR; Li, Y; Yeung, PP | 1 |
| Carandang, C; Carrey, N; Gardner, DM; Kutcher, S; Santor, D | 1 |
| Bauer, M; Froud, DM; Jain, R; Kajdasz, DK; Perahia, DG; Pritchett, YL; Raskin, J; Russell, JM; Spencer, KA; Thase, ME; Walker, DJ | 1 |
| Damsbo, N; Hemels, ME; Le Lay, A; Stage, KB; Sørensen, J | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Biggs, MM; Fava, M; Friedman, ES; Hollon, SD; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Dierkes, W; Linden, M; Munz, T | 1 |
| Alves Valle, E; Araújo Silva, S; Avila de Melo, R; da Costa Júnior, AL; de Souza Neto, JJ; de Vasconcelos Cunha, UG; Faria Alves, VX; Lopes Rocha, F; Magalhães Scoralick, F; Martins de Oliveira, F; Mendes Brega, R; Sakurai, E | 1 |
| Boovariwala, A; Ginovart, N; Houle, S; Meyer, JH; Rusjan, P; Sagrati, S; Sokolov, S; Spencer, EP; Voineskos, AN; Wilson, AA | 1 |
| Aharonovich, E; Bisaga, A; Brooks, DJ; Garawi, F; Levin, FR; Mariani, J; Nunes, EV; Raby, W; Rubin, E | 1 |
| Chen, YC; Lu, RB; Wu, YS | 1 |
| Berlim, MT; Turecki, MG | 1 |
| Barbuzza, O; Borgia, F; Guarneri, B; Vaccaro, M | 1 |
| Ahmed, S; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Musgnung, J; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Schatzberg, AF; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM | 1 |
| Black, JL; McAlpine, DE; Mrazek, DA; O'Kane, DJ | 1 |
| Heeren, TJ; Kok, RM; Nolen, WA; Vink, D | 1 |
| Gillman, K | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Hsiao, MC; Liu, CY | 1 |
| Fava, M; Papakostas, GI; Thase, ME | 1 |
| Jagadheesan, K; Lusicic, A | 1 |
| Alvarez, E; Guilleminault, C; Lemoine, P | 1 |
| Byrd, EH; Chismar, R; Dey, S; Holtzheimer, PE; Kelley, ME; McDonald, WM; McWhorter, K; Meeks, TW; Mufti, M; Quinn, S; Vito, N; Young, R | 1 |
| Alpert, JE; Balasubramani, GK; Biggs, MM; Carmin, CN; Fava, M; Howland, R; Leuchter, A; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S | 1 |
| Alexandrino-Silva, C; de Andrade, AG; de Toledo Ferraz Alves, TC; Nadalini Mauá, FH | 1 |
| Akkaya, C; Cangur, S; Eker, SS; Kirli, S; Sarandol, A; Sarandol, E | 1 |
| Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS | 1 |
| Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Case, K; Cramer-Bornemann, M; Hurwitz, TD; Kim, SW; Schenck, CH | 1 |
| Cox, SK; Reeves, RR | 1 |
| Lyons, JE; Symon, J | 1 |
| Bria, P; Camardese, G; Picello, A | 1 |
| Bares, M; Brunovsky, M; Höschl, C; Kopecek, M; Kozeny, J; Krajca, V; Novak, T; Sos, P; Stopkova, P | 1 |
| Fulton, K; Kennedy, SH; Rasmussen, J; Rizvi, S | 1 |
| Amsterdam, JD; Shults, J; Shwarz, M; Wang, CH | 1 |
| Freemantle, N | 1 |
| Brilmyer, M; Kant, R; Zeiler, D; Zimmer, B | 1 |
| Rajagopalan, M | 1 |
| Spier, SA | 1 |
| Kubb, R; Lyndon, B; Walter, G | 1 |
| Chouinard, G; Dallal, A | 1 |
| Amsterdam, J | 1 |
| Arikian, SR; Casciano, J; Doyle, JJ; Einarson, TR | 1 |
| Corruble, E; Guelfi, JD | 1 |
| Peretti, CS | 1 |
| Poirier, MF | 1 |
| Reznik, I; Rosen, B; Rosen, Y | 1 |
| Brager, N; Tham, CJ; Trew, M | 1 |
| Blauer, F; Fleisch, MC; Gubler, JG; Kuhn, M; Scherer, TA | 1 |
| Blanco, C; Mullen, LS; Roose, SP; Vaughan, R; Vaughan, SC | 1 |
| Levin, FR; McDowell, DM; Nunes, EV; Seracini, AM | 1 |
| Benedictis, E; D'Arrigo Busnello, E; De Campos, JA; De Cassia Rodrigues, RL; Gentil, V; Juruena, MF; Kerr-Correa, F; Lafer, B; Moreno, DH; Moreno, R; Tiosso, A | 1 |
| Anisman, H; Griffiths, J; Merali, Z; Ravindran, AV; Zaharia, MD | 1 |
| Amsterdam, JD; Garcia-España, F | 1 |
| Golden, RN; Nicholas, L | 1 |
| Kienke, AS; Rosenbaum, JF | 1 |
| Friedman, ES; Howland, RH; Thase, ME | 1 |
| Evans, DL; Staab, JP | 1 |
| Ninan, PT | 1 |
| Behar, D; Schaller, JL | 1 |
| Burrows, G; Flynn, P; George, T; Mitchell, P; Polonowita, A; Schweitzer, I; Theodoros, M; Tuckwell, V | 1 |
| Baumann, P; Preisig, M; Zullino, D | 1 |
| Cook, IA; Leuchter, AF | 1 |
| Arikian, S; Casciano, J; Casciano, R; Doyle, J | 1 |
| Ishigooka, J | 1 |
| Perry, CM; Wellington, K | 1 |
| Cheng, CY; Hong, CJ; Huo, SJ; Tsai, SJ; Wu, WH | 1 |
| Abrams, M; Cook, IA; Leuchter, AF; Morgan, M; Witte, EA | 1 |
| Entsuah, AR; Huang, H; Thase, ME | 1 |
| Bagby, RM; Kennedy, SH; Vanderkooy, JD | 1 |
| Elizagarate, E; Gonzalez, N; Gonzalez-Pinto, A; Gutierrez, M; Mico, JA; Perez de Heredia, JL | 1 |
| Amsterdam, JD; Hornig-Rohan, M | 1 |
| Abrams, M; Cook, IA; Leuchter, AF; Morgan, M; Rosenberg, S; Stubbeman, WF; Uijtdehaage, SH; Witte, E | 1 |
79 review(s) available for venlafaxine hydrochloride and Depression, Involutional
| Article | Year |
|---|---|
[The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Duloxetine Hydrochloride; Humans; Middle Aged; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2022 |
A state-of-the-art review on the nanomaterial-based sensor for detection of venlafaxine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Nanostructures; Photolysis; Venlafaxine Hydrochloride | 2022 |
Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.
Topics: Animals; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Humans; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fluoxetine; Humans; Mirtazapine; Network Meta-Analysis; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2019 |
No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Mirtazapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2020 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Vortioxetine for depression in adults.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Patient Dropouts; Piperazines; Placebos; Randomized Controlled Trials as Topic; Remission Induction; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine | 2017 |
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Prognosis; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Differences in the placebo response in duloxetine and venlafaxine trials.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebo Effect; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2018 |
A quantitative review on outcome-to-antidepressants in melancholic unipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Humans; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Topics: Adult; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Phenotype; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Failure; Venlafaxine Hydrochloride | 2019 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Mirtazapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Venlafaxine Hydrochloride | 2019 |
Venlafaxine pharmacogenetics: a comprehensive review.
Topics: Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Genotype; Humans; Pharmacogenetics; Polymorphism, Genetic; Venlafaxine Hydrochloride | 2019 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials.
Topics: Adrenergic Uptake Inhibitors; Cyclohexanols; Demography; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Randomized Controlled Trials as Topic; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2014 |
Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Depression after spinal cord injury and medication: The journey continues.
Topics: Depressive Disorder, Major; Female; Humans; Male; Pain; Spinal Cord Injuries; Venlafaxine Hydrochloride | 2014 |
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Benzofurans; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Thiophenes; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2014 |
[Venlafaxine-induced delirium mediated by high doses].
Topics: Aged; Antidepressive Agents; Comorbidity; Confusion; Delirium; Depressive Disorder, Major; Dopamine; Dose-Response Relationship, Drug; Drug Substitution; Drug Synergism; Female; Humans; Lorazepam; Models, Neurological; Norepinephrine; Polypharmacy; Psychotropic Drugs; Recurrence; Sertraline; Venlafaxine Hydrochloride | 2015 |
First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Cohort Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Pregnancy; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2016 |
Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Vilazodone Hydrochloride | 2016 |
Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
Topics: Adolescent; Antidepressive Agents; Child; Cyclopropanes; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Male; Milnacipran; Placebos; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Pharmacogenetics; Practice Guidelines as Topic; Precision Medicine; Prescription Drugs; Venlafaxine Hydrochloride | 2016 |
A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Venlafaxine Hydrochloride | 2017 |
[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
Topics: Affect; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Mianserin; Mirtazapine; Patient Satisfaction; Personality Inventory; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Suicide Prevention; Thiophenes; Time Factors; Treatment Refusal; Venlafaxine Hydrochloride | 2008 |
New antidepressants for older people: a critical review of the evidence base.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Fluoxetine; Humans; Patient Care Team; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Desvenlafaxine: another "me too" drug?
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Costs; Drug Interactions; Humans; Remission Induction; Venlafaxine Hydrochloride | 2008 |
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antineoplastic Agents, Hormonal; Biotransformation; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hot Flashes; Humans; Middle Aged; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Humans; Middle Aged; Psychiatric Status Rating Scales; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Reference Values; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Venlafaxine Hydrochloride | 2009 |
[Severe forms of depression: the efficacy of escitalopram].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2009 |
Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2009 |
[Cholinesterase inhibitors and depression in the elderly].
Topics: Aged; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Cognition Disorders; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; Neuropsychological Tests; Venlafaxine Hydrochloride | 2010 |
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Norepinephrine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Duloxetine Hydrochloride; Humans; Pharmacological Phenomena; Randomized Controlled Trials as Topic; Remission Induction; Therapeutic Equivalency; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
Topics: Adult; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Evidence-Based Medicine; Female; Humans; Male; Odds Ratio; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Venlafaxine Hydrochloride | 2012 |
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
Topics: Adolescent; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Mechanism of action of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |
A pharmacoeconomic evaluation of major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Cost-Benefit Analysis; Critical Pathways; Cyclohexanols; Decision Trees; Depressive Disorder, Major; Economics, Pharmaceutical; Humans; Venlafaxine Hydrochloride | 2003 |
Dual action antidepressants and some important considerations.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Histamine H1 Antagonists; Humans; Mianserin; Milnacipran; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Venlafaxine Hydrochloride; Weight Gain | 2003 |
Treatment of pain syndromes with venlafaxine.
Topics: Analgesics; Animals; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Pain; Pain, Postoperative; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2004 |
Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2004 |
SNRIs in the management of acute major depressive disorder.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Placebos; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Humans; Long-Term Care; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Outpatients; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Treatment Refusal; Venlafaxine Hydrochloride | 2005 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Using metaanalysis to evaluate evidence: practical tips and traps.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Seasonal Affective Disorder; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2005 |
Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Cost of Illness; Cost-Benefit Analysis; Cyclohexanols; Decision Trees; Depressive Disorder, Major; Duloxetine Hydrochloride; Economics, Pharmaceutical; Health Care Costs; Humans; Middle Aged; Models, Econometric; Norepinephrine; Ontario; Outpatients; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; In Vitro Techniques; Milnacipran; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride; Vesicular Monoamine Transport Proteins | 2005 |
Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Topics: Adult; Cyclohexanols; Data Collection; Delayed-Action Preparations; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Patient Dropouts; Randomized Controlled Trials as Topic; Review Literature as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2007 |
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dopamine; Dopamine Uptake Inhibitors; Drug Delivery Systems; Drug Design; Drug Therapy, Combination; Humans; Morpholines; Nerve Net; Neurons; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2006 |
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Regression Analysis; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Models, Econometric; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.
Topics: Bupropion; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Humans; Mianserin; Mirtazapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Patient Dropouts; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Imipramine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
[Therapeutic action lag time and resistance to treatment].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Dibenzocycloheptenes; Drug Resistance; Fluoxetine; Hospitalization; Humans; Severity of Illness Index; Time Factors; Venlafaxine Hydrochloride | 1999 |
Antidepressant efficacy of venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Efficacy of venlafaxine in the treatment of severe depression.
Topics: Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Venlafaxine and treatment-resistant depression.
Topics: Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2000 |
Efficacy of venlafaxine in geriatric depression.
Topics: Aged; Cyclohexanols; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Use of venlafaxine in other psychiatric disorders.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fibromyalgia; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Trichotillomania; Venlafaxine Hydrochloride | 2000 |
The health economic impact of antidepressant usage from a payer's perspective: a multinational study.
Topics: Acute Disease; Algorithms; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Costs; Europe; Health Care Costs; Health Policy; Humans; North America; Venlafaxine Hydrochloride | 2001 |
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
255 trial(s) available for venlafaxine hydrochloride and Depression, Involutional
| Article | Year |
|---|---|
Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Medication Adherence; Venlafaxine Hydrochloride | 2022 |
Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2022 |
Impact of response shift effects in the assessment of self-reported depression during treatment: Insights from a rTMS versus Venlafaxine randomized controlled trial.
Topics: Depression; Depressive Disorder, Major; Humans; Self Report; Treatment Outcome; Venlafaxine Hydrochloride | 2023 |
Heartbeat-Evoked Potential in Major Depressive Disorder: A Biomarker for Differential Treatment Prediction between Venlafaxine and rTMS?
Topics: Biomarkers; Citalopram; Depressive Disorder, Major; Evoked Potentials; Heart Rate; Humans; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2023 |
Normalization of EEG in depression after antidepressant treatment with sertraline? A preliminary report.
Topics: Adult; Alpha Rhythm; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.
Topics: Aged; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressive Disorder, Major; Female; Humans; Logistic Models; Male; Middle Aged; Suicidal Ideation; Survival Analysis; Venlafaxine Hydrochloride | 2019 |
Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain; Citalopram; Connectome; Depressive Disorder, Major; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Remission Induction; Sertraline; Venlafaxine Hydrochloride; Young Adult | 2020 |
Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.
Topics: Aged; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Neurocognitive Disorders; Neuropsychological Tests; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment.
Topics: Adult; Alpha Rhythm; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder, Major; Electroencephalography; Female; Frontal Lobe; Functional Laterality; Humans; Male; Prospective Studies; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Topics: Algorithms; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Clinical Decision Rules; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Likelihood Functions; Prospective Studies; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Trazodone; Venlafaxine Hydrochloride; Young Adult | 2020 |
Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Algorithms; Antidepressive Agents; Citalopram; Clinical Decision Rules; Depressive Disorder, Major; Electroencephalography; Female; Humans; Machine Learning; Male; Middle Aged; Prognosis; Prospective Studies; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
Topics: Adult; Antidepressive Agents; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine.
Topics: Biomarkers; Depressive Disorder, Major; Folic Acid; Humans; Paroxetine; Venlafaxine Hydrochloride | 2021 |
Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults.
Topics: Accidental Falls; Aged; Aged, 80 and over; Blood Pressure; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Hypotension, Orthostatic; Male; Middle Aged; Prospective Studies; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2020 |
Psychomotor Retardation and the prognosis of antidepressant treatment in patients with unipolar Psychotic Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Prognosis; Psychotic Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis.
Topics: Antidepressive Agents; Cluster Analysis; Cyclohexanols; Data Analysis; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Venlafaxine Hydrochloride | 2020 |
Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy.
Topics: Aged; Aged, 80 and over; Depressive Disorder, Major; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Male; Middle Aged; Motor Cortex; Neural Inhibition; Neuronal Plasticity; Outcome Assessment, Health Care; Serotonin and Noradrenaline Reuptake Inhibitors; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride | 2021 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmenopause; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.
Topics: Aged; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Lithium; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 2022 |
Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study.
Topics: Adolescent; Adult; Biomarkers; Chemokine CXCL5; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Venlafaxine Hydrochloride; Young Adult | 2017 |
A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipramine; Lithium Compounds; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Venlafaxine Hydrochloride | 2017 |
Bone Turnover with Venlafaxine Treatment in Older Adults with Depression.
Topics: Aged; Biomarkers; Bone Remodeling; Collagen Type I; Depressive Disorder, Major; Female; Humans; Male; Procollagen; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2017 |
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Quality of Life; Social Adjustment; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2017 |
Vascular risk factors in older patients with depression: outcome of electroconvulsive therapy versus medication.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Logistic Models; Male; Middle Aged; Nortriptyline; Risk Factors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Vascular Diseases; Venlafaxine Hydrochloride | 2018 |
A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
Topics: Adult; Antidepressive Agents; Blood Pressure; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Venlafaxine Hydrochloride | 2017 |
Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
Topics: Adult; Age Factors; Antidepressive Agents; Citalopram; Cohort Studies; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Hippocampus; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Organ Size; Pattern Recognition, Automated; Prognosis; Psychiatric Status Rating Scales; Remission Induction; Sertraline; Venlafaxine Hydrochloride | 2018 |
Effects of venlafaxine versus lithium monotherapy on quality of life in bipolar II major depressive disorder: Findings from a double-blind randomized controlled trial.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Lithium Carbonate; Male; Middle Aged; Quality of Life; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Humans; Lithium Compounds; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Secondary Prevention; Venlafaxine Hydrochloride | 2018 |
Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Depressive Disorder, Major; Drug Combinations; Female; Humans; Male; Middle Aged; Olanzapine; Severity of Illness Index; Venlafaxine Hydrochloride; Young Adult | 2018 |
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body Mass Index; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Overweight; Patient Selection; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bipolar Disorder; Bupropion; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outpatients; Self Report; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Biomarkers; Citalopram; Depression; Depressive Disorder, Major; Female; Heart Rate; Humans; Male; Middle Aged; Prognosis; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2019 |
Trajectories in Cerebral Blood Flow Following Antidepressant Treatment in Late-Life Depression: Support for the Vascular Depression Hypothesis.
Topics: Antidepressive Agents, Second-Generation; Cerebrovascular Circulation; Depressive Disorder, Major; Female; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vascular Diseases; Venlafaxine Hydrochloride | 2018 |
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Mirtazapine; Outcome Assessment, Health Care; Psychometrics; Risk Assessment; Self Report; Single-Blind Method; Suicidal Ideation; Venlafaxine Hydrochloride | 2019 |
Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Comorbidity; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Psychiatric Status Rating Scales; Recurrence; Retrospective Studies; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Exercise for Depression: A Feasibility Trial Exploring Neural Mechanisms.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Brain; Depressive Disorder, Major; Double-Blind Method; Exercise Therapy; Feasibility Studies; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pennsylvania; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride; Young Adult | 2019 |
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2019 |
Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Cognition; Depressive Disorder, Major; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2020 |
Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.
Topics: Absorptiometry, Photon; Adiposity; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Genome-Wide Association Study; Humans; Male; Polymorphism, Single Nucleotide; Venlafaxine Hydrochloride; Weight Gain | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Hippocampal Subfields in Acute and Remitted Depression-an Ultra-High Field Magnetic Resonance Imaging Study.
Topics: Adolescent; Adult; Affect; Antidepressive Agents, Second-Generation; Austria; Citalopram; Depressive Disorder, Major; Drug Substitution; Female; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2019 |
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.
Topics: Adult; Biomarkers; C-Reactive Protein; Depressive Disorder, Major; Female; Humans; Interleukin-10; Interleukin-6; Male; Middle Aged; Paroxetine; Treatment Outcome; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride; Young Adult | 2019 |
Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Psychometrics; Secondary Prevention; Sexual Dysfunction, Physiological; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2013 |
Dynamic prediction of treatment response in late-life depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Aripiprazole; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Remission Induction; Severity of Illness Index; Signal Detection, Psychological; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
The change of insulin levels after six weeks antidepressant use in drug-naïve major depressive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Risk; Severity of Illness Index; Venlafaxine Hydrochloride; Young Adult | 2013 |
Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Catechol O-Methyltransferase; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Methionine; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Psychiatric Status Rating Scales; Time Factors; Valine; Venlafaxine Hydrochloride; Young Adult | 2013 |
A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imipramine; Inpatients; Male; Middle Aged; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2013 |
Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Brain; California; Citalopram; Clinical Protocols; Cognition; Cyclohexanols; Depressive Disorder, Major; Diffusion Tensor Imaging; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; New South Wales; Predictive Value of Tests; Prospective Studies; Psychiatric Status Rating Scales; Research Design; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Research Design; Spinal Cord Injuries; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2014 |
Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes?
Topics: Affect; Antidepressive Agents; Conditioning, Classical; Cyclohexanols; Depressive Disorder, Major; Drug Tolerance; Electroencephalography; Female; Humans; Learning; Models, Biological; Statistics, Nonparametric; Substance-Related Disorders; Venlafaxine Hydrochloride | 2013 |
Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depression; Depressive Disorder, Major; Double-Blind Method; Emotions; Fluoxetine; Functional Neuroimaging; Humans; Prefrontal Cortex; Venlafaxine Hydrochloride | 2013 |
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Venlafaxine Hydrochloride | 2015 |
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Menopause; Middle Aged; Placebos; Proportional Hazards Models; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Mianserin; Middle Aged; Mirtazapine; Placebos; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Computer-Assisted; Double-Blind Method; Electroencephalography; Female; Humans; Male; Middle Aged; Prefrontal Cortex; Reproducibility of Results; Sensitivity and Specificity; Theta Rhythm; Transcranial Magnetic Stimulation; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antidepressive Agents; Cognition; Comorbidity; Depressive Disorder, Major; Desipramine; Double-Blind Method; Female; Humans; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride; Young Adult | 2014 |
Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Nortriptyline; Remission Induction; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients.
Topics: Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Predictive Value of Tests; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Increased platelet count after treatment with venlafaxine or mirtazapine in depressed patients.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Platelet Count; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2015 |
Differences in quality of life outcomes among depressed spinal cord injury trial participants.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Psychiatric Status Rating Scales; Quality of Life; Spinal Cord Injuries; Venlafaxine Hydrochloride; Young Adult | 2015 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Outpatients; Predictive Value of Tests; Single-Blind Method; Sleep Initiation and Maintenance Disorders; Substance-Related Disorders; Surveys and Questionnaires; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2015 |
Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.
Topics: Adolescent; Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Neuralgia; Nociceptive Pain; Pain; Psychiatric Status Rating Scales; Spinal Cord Injuries; Trauma Severity Indices; Venlafaxine Hydrochloride; Young Adult | 2015 |
A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cognition; Computers; Delayed-Action Preparations; Depressive Disorder, Major; Emotions; Female; Humans; Male; Middle Aged; Prognosis; Psychiatric Status Rating Scales; Psychological Tests; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Risk Factors; Sertraline; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
Topics: Adolescent; Adult; Chronic Disease; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Spinal Cord Injuries; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
Topics: Antidepressive Agents; Clinical Protocols; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Genotype; Humans; Nortriptyline; Pharmacogenetics; Sample Size; Venlafaxine Hydrochloride | 2015 |
Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine.
Topics: Acetamides; Adult; Automobile Driving; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychomotor Performance; Venlafaxine Hydrochloride; Visual Perception | 2015 |
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anxiety; Asia; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine; Young Adult | 2015 |
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Outpatients; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Polymorphism, Single Nucleotide; Remission Induction; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Topics: Adult; Amygdala; Antidepressive Agents; Case-Control Studies; Citalopram; Depressive Disorder, Major; Emotions; Facial Expression; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Oxygen; Photic Stimulation; Predictive Value of Tests; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
Topics: Adult; Antidepressive Agents; Australia; Citalopram; Cognition; Depressive Disorder, Major; Executive Function; Female; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Prefrontal Cortex; Prognosis; Psychiatric Status Rating Scales; Regression Analysis; Remission Induction; Sertraline; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2016 |
Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
Topics: Adult; Antidepressive Agents; Brain Mapping; Citalopram; Depressive Disorder, Major; Electroencephalography; Female; Frontal Lobe; Gyrus Cinguli; Humans; Male; Prospective Studies; Psychiatric Status Rating Scales; Remission Induction; Sertraline; Severity of Illness Index; Theta Rhythm; Venlafaxine Hydrochloride | 2015 |
Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Phototherapy; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Black or African American; Depressive Disorder, Major; Female; Humans; Kaplan-Meier Estimate; Male; Patient Dropouts; Proportional Hazards Models; Recurrence; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride; White People | 2015 |
Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Brain; Brain Mapping; Citalopram; Depressive Disorder, Major; Electroencephalography; Evoked Potentials; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Prospective Studies; Sertraline; Sex Characteristics; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk Factors; Severity of Illness Index; Socioeconomic Factors; Venlafaxine Hydrochloride; Young Adult | 2016 |
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
Topics: Adult; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Self-Injurious Behavior; Suicidal Ideation; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Evaluating the Psychometric Properties and Responsiveness to Change of 3 Depression Measures in a Sample of Persons With Traumatic Spinal Cord Injury and Major Depressive Disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Disability Evaluation; Female; Humans; Male; Middle Aged; Physical Therapy Modalities; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Severity of Illness Index; Spinal Cord Injuries; Venlafaxine Hydrochloride | 2016 |
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Aripiprazole; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Set, Psychology; Severity of Illness Index; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Assessment of the relationship of spiritual well-being to depression and quality of life for persons with spinal cord injury.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Quality of Life; Spinal Cord Injuries; Spirituality; Surveys and Questionnaires; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2017 |
Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Net; Predictive Value of Tests; Psychiatric Status Rating Scales; Sertraline; Venlafaxine Hydrochloride; White Matter; Young Adult | 2016 |
Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Least-Squares Analysis; Lisdexamfetamine Dimesylate; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression.
Topics: Adult; Bupropion; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2017 |
Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Late Onset Disorders; Male; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases, Genetic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Neuronal Plasticity; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Remission Induction; Second Messenger Systems; Treatment Outcome; Venlafaxine Hydrochloride | 2017 |
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cyclohexanols; Depressive Disorder, Major; Enzyme-Linked Immunosorbent Assay; Female; Humans; Linear Models; Male; Middle Aged; Psychiatric Status Rating Scales; Sertraline; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Female; Half-Life; Humans; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Suicide; Venlafaxine Hydrochloride | 2008 |
Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chlorates; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Venlafaxine Hydrochloride | 2009 |
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Middle Aged; Personality Inventory; Primary Health Care; Prognosis; Retreatment; Secondary Prevention; Sertraline; Venlafaxine Hydrochloride | 2008 |
Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chi-Square Distribution; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Matched-Pair Analysis; Neuropsychological Tests; Paroxetine; Reference Values; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Lithium Carbonate; Long-Term Care; Male; Middle Aged; Personality Inventory; Psychometrics; Retreatment; Tachyphylaxis; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2008 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2010 |
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Recurrence; Risk Assessment; Time Factors; Treatment Failure; Venlafaxine Hydrochloride | 2008 |
Outcome of late-life depression after 3 years of sequential treatment.
Topics: Age of Onset; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Nortriptyline; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
Topics: Brain; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2009 |
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Olanzapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Weight Gain | 2009 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Topics: Adult; Antidepressive Agents; Blood Pressure; Constipation; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dizziness; Double-Blind Method; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Statistics as Topic; Venlafaxine Hydrochloride; Xerostomia | 2009 |
Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Personality Assessment; Prefrontal Cortex; Psychometrics; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride | 2009 |
Early response as predictor of final remission in elderly depressed patients.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Humans; Middle Aged; Nortriptyline; Remission Induction; ROC Curve; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression.
Topics: Adolescent; Adult; Aged; Algorithms; Choice Behavior; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Interview, Psychological; Male; Middle Aged; Psychotherapy, Brief; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants.
Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; G-Protein-Coupled Receptor Kinase 2; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Messenger; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Liver Function Tests; Male; Middle Aged; Suicide; Venlafaxine Hydrochloride; Young Adult | 2009 |
Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Cognitive Behavioral Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Fluorodeoxyglucose F18; Glucose; Gyrus Cinguli; Humans; Male; Middle Aged; Positron-Emission Tomography; Venlafaxine Hydrochloride; Young Adult | 2009 |
A comparison of several approaches for choosing between working correlation structures in generalized estimating equation analysis of longitudinal binary data.
Topics: Antidepressive Agents, Second-Generation; Biometry; Computer Simulation; Cyclohexanols; Depressive Disorder, Major; Humans; Linear Models; Lithium Compounds; Longitudinal Studies; Prospective Studies; Randomized Controlled Trials as Topic; Regression Analysis; Venlafaxine Hydrochloride | 2009 |
Frontal EEG predictors of treatment outcome in major depressive disorder.
Topics: Adolescent; Adult; Cyclohexanols; Depressive Disorder, Major; Electroencephalography; Female; Frontal Lobe; Humans; Male; Middle Aged; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Cross-Over Studies; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Prospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
Topics: Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Numerical Analysis, Computer-Assisted; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Somatosensory Disorders; Venlafaxine Hydrochloride | 2009 |
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Tachyphylaxis; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antigens, CD; Cyclohexanols; Depressive Disorder, Major; Female; Flow Cytometry; Fluoxetine; Humans; Lymphocyte Subsets; Male; Statistics, Nonparametric; Venlafaxine Hydrochloride; Young Adult | 2010 |
Substance use and the treatment of resistant depression in adolescents.
Topics: Adolescent; Alcoholism; Antidepressive Agents, Second-Generation; Attention Deficit and Disruptive Behavior Disorders; Child Abuse; Child Abuse, Sexual; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Conduct Disorder; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Drug Resistance; Drug Therapy, Combination; Family Conflict; Female; Humans; Illicit Drugs; Male; Personality Inventory; Psychometrics; Psychotropic Drugs; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Suicidal Ideation; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Long-term response to successful acute pharmacological treatment of psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imipramine; Long-Term Care; Male; Middle Aged; Netherlands; Quetiapine Fumarate; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.
Topics: Adolescent; Adult; Aged; Bupropion; Citalopram; Cognitive Behavioral Therapy; Cyclohexanols; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Female; Humans; Male; Middle Aged; Primidone; Remission Induction; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
Topics: Adult; Biomarkers; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Receptors, Kainic Acid; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Sertraline; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Huntington Disease; Irritable Mood; Male; Middle Aged; Nausea; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; France; Humans; Male; Middle Aged; Milnacipran; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Venlafaxine Hydrochloride; Young Adult | 2009 |
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Psychometrics; Secondary Prevention; Venlafaxine Hydrochloride | 2010 |
Venlafaxine, but not mirtazapine lowers retinol-binding protein 4 serum concentrations in nondiabetic depressed patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Retinol-Binding Proteins, Plasma; Venlafaxine Hydrochloride | 2010 |
Correlation between patient and clinician assessments of depression severity in the PREVENT study.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics as Topic; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Circadian Rhythm; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Hydrocortisone; Male; Mianserin; Middle Aged; Mirtazapine; Psychiatric Status Rating Scales; Saliva; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain; California; Causality; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Mood Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Suicide; Venlafaxine Hydrochloride | 2010 |
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Long-Term Care; Longitudinal Studies; Male; Middle Aged; Quality of Life; Secondary Prevention; Social Adjustment; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Neuropsychological Tests; Pharmacogenetics; Polymorphism, Single Nucleotide; Taiwan; Venlafaxine Hydrochloride | 2010 |
Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Personality Inventory; Psychometrics; Slovenia; Venlafaxine Hydrochloride; Young Adult | 2010 |
Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Basal Ganglia; Brain; Cyclohexanols; Depressive Disorder, Major; Emotions; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Mianserin; Mirtazapine; Prefrontal Cortex; Psychiatric Status Rating Scales; Time Factors; Venlafaxine Hydrochloride | 2011 |
TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
Topics: Adult; Asian People; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequency; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Taiwan; Treatment Outcome; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2011 |
Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Patient Education as Topic; Patient Satisfaction; Primary Health Care; Program Evaluation; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Social Support; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2010 |
Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Neural correlates of treatment outcome in major depression.
Topics: Adult; Affect; Antidepressive Agents; Biomarkers; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Face; Female; Frontal Lobe; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Nerve Net; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks.
Topics: Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Humans; Lithium; Male; Middle Aged; Nortriptyline; Quality of Life; Time Factors; Venlafaxine Hydrochloride | 2011 |
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Australia; Citalopram; Cognition; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Electroencephalography; Emotions; Europe; Female; Humans; Male; Middle Aged; Neuropsychological Tests; New Zealand; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Research Design; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Behavior; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2011 |
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
Topics: Activities of Daily Living; Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Prospective Studies; Triglycerides; Venlafaxine Hydrochloride | 2011 |
Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Norepinephrine; Remission Induction; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Monitoring; Drug Resistance; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Venlafaxine Hydrochloride | 2011 |
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Middle Aged; Personality Inventory; Recurrence; Selective Serotonin Reuptake Inhibitors; Self Report; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Follow-Up Studies; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Psychiatric Status Rating Scales; Theta Rhythm; Venlafaxine Hydrochloride | 2011 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Cyclohexanols; Depression; Depressive Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outpatients; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Sulfides; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2012 |
Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders.
Topics: Adolescent; Adult; Aged; Algorithms; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Resistance; Drug Substitution; Female; Humans; Male; Middle Aged; Placebos; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.
Topics: Adult; Anhedonia; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Emotions; Female; Fluoxetine; Follow-Up Studies; Functional Laterality; Humans; Image Processing, Computer-Assisted; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Prefrontal Cortex; Psychiatric Status Rating Scales; Pupil; Surveys and Questionnaires; Venlafaxine Hydrochloride; Young Adult | 2011 |
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Neurotransmitter Uptake Inhibitors; Paroxetine; Placebos; Tropanes; Venlafaxine Hydrochloride | 2012 |
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Regression Analysis; Risk Factors; Self Report; Single-Blind Method; Suicidal Ideation; Surveys and Questionnaires; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Ethnicity; Female; Humans; Male; Middle Aged; Patient Dropouts; Psychiatric Status Rating Scales; Psychotherapy, Brief; Sertraline; Sex Characteristics; Venlafaxine Hydrochloride | 2012 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Likelihood Functions; Male; Middle Aged; Personality Inventory; Psychometrics; Quality of Life; Sertraline; United States; Venlafaxine Hydrochloride; Young Adult | 2012 |
Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Migraine Disorders; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Venlafaxine Hydrochloride | 2012 |
Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Labeling; Drug Resistance; Humans; Patient Selection; Selective Serotonin Reuptake Inhibitors; Suicide Prevention; Venlafaxine Hydrochloride | 2012 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sleep Wake Disorders; Trazodone; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Does prior antidepressant treatment of major depression impact brain function during current treatment?
Topics: Adult; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Los Angeles; Male; Middle Aged; Neurons; Prefrontal Cortex; Psychiatric Status Rating Scales; Self Report; Single-Blind Method; Theta Rhythm; Venlafaxine Hydrochloride | 2012 |
Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
Topics: Adolescent; Affect; Anhedonia; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Resistance; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Personality Assessment; Psychometrics; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Topics: Adult; Aged; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pindolol; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Recovery and subsequent recurrence in patients with recurrent major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Psychiatric Status Rating Scales; Recovery of Function; Risk Factors; Secondary Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Humans; Mianserin; Mirtazapine; Recurrence; Severity of Illness Index; Substance-Related Disorders; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: a prospective longitudinal study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Asian People; Cyclohexanols; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Suicidal Ideation; Tumor Necrosis Factor-alpha; Up-Regulation; Venlafaxine Hydrochloride; Young Adult | 2013 |
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Prognosis; Prospective Studies; Psychometrics; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Autonomic Nervous System; Case-Control Studies; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Entropy; Female; Heart Rate; Humans; Recurrence; Respiratory Rate; Venlafaxine Hydrochloride | 2012 |
Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
Topics: Acetamides; Adolescent; Adult; Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Patient Dropouts; Pilot Projects; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2012 |
Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Norepinephrine; Venlafaxine Hydrochloride | 2012 |
Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.
Topics: Affect; Antidepressive Agents; Biological Availability; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Nucleus Accumbens; Psychiatric Status Rating Scales; Reward; Sickness Impact Profile; Treatment Outcome; Venlafaxine Hydrochloride; Visual Cortex | 2013 |
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Abuse; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Placebos; Psychiatric Status Rating Scales; Quality of Life; Recurrence; Self Report; Severity of Illness Index; Single-Blind Method; Suicidal Ideation; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Medication Adherence; Recurrence; Selective Serotonin Reuptake Inhibitors; Treatment Failure; Venlafaxine Hydrochloride | 2013 |
Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antimanic Agents; Cognition; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lithium; Male; Middle Aged; Psychiatric Status Rating Scales; Sample Size; Secondary Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
Topics: Aged; Antidepressive Agents, Second-Generation; Biomarkers; Bone Resorption; Collagen Type I; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Biotransformation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2002 |
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Body Weight; Cross-Over Studies; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Leptin; Longitudinal Studies; Male; Mianserin; Middle Aged; Mirtazapine; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride | 2002 |
Single-blind comparison of venlafaxine and nortriptyline in elderly major depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Psychiatric Status Rating Scales; Single-Blind Method; Venlafaxine Hydrochloride | 2003 |
Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2003 |
Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Hospitalization; Humans; Male; Paroxetine; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Venlafaxine versus placebo in the preventive treatment of recurrent major depression.
Topics: Adult; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Observer Variation; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2004 |
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Dysthymic Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Predictors of improved mood over time in clinical trials for major depression.
Topics: Adult; Affect; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2004 |
Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Clonidine; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Norepinephrine; Personality Inventory; Pyrimidines; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Weight; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Venlafaxine Hydrochloride | 2004 |
S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.
Topics: Adult; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; S-Adenosylmethionine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2004 |
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cyclohexanols; Demography; Depressive Disorder, Major; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Health Care Costs; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Venlafaxine Hydrochloride | 2005 |
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Placebos; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study.
Topics: Ambulatory Care; Antidepressive Agents, Tricyclic; Attitude to Health; Cohort Studies; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Humans; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Tachyphylaxis; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
Topics: Adult; Ambulatory Care; Blood Pressure; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Health Status; Humans; Male; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial.
Topics: Adult; Citalopram; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Hospitalization; Humans; Male; Middle Aged; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Humans; Mianserin; Middle Aged; Mirtazapine; Patient Compliance; Psychiatric Status Rating Scales; Tablets; Time Factors; Venlafaxine Hydrochloride | 2006 |
Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
Topics: Ambulatory Care; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Treatment Failure; Venlafaxine Hydrochloride | 2006 |
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Demography; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2006 |
Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Blood Pressure; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Time Factors; Treatment Outcome; Tyramine; Venlafaxine Hydrochloride | 2007 |
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mass Screening; Middle Aged; Olanzapine; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Refusal; Venlafaxine Hydrochloride | 2006 |
Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Cyclohexanols; Dehydroepiandrosterone; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychological Tests; Remission Induction; Statistics, Nonparametric; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-12; Male; Middle Aged; Paroxetine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Drug Evaluation; Drug Interactions; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Venlafaxine Hydrochloride | 2006 |
Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Placebos; Prefrontal Cortex; Psychiatric Status Rating Scales; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Theta Rhythm; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Escitalopram versus venlafaxine XR in the treatment of depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Quality of Life; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.
Topics: Age of Onset; Aged; Arrhythmias, Cardiac; Cardiovascular Diseases; Cognition Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Monitoring; Electrocardiography; Female; Guidelines as Topic; Heart Rate; Humans; Hypertension; Hypotension, Orthostatic; Male; Neuropsychological Tests; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tachycardia; Venlafaxine Hydrochloride | 2006 |
Keeping our eyes on STAR*D.
Topics: Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Lithium; Mianserin; Mirtazapine; Placebos; Research Design; Tranylcypromine; Treatment Outcome; Triiodothyronine; Venlafaxine Hydrochloride | 2006 |
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Mianserin; Middle Aged; Mirtazapine; Psychiatric Status Rating Scales; Tranylcypromine; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Patient Compliance; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; History, Ancient; Humans; Secondary Prevention; Venlafaxine Hydrochloride | 2006 |
Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Arousal; Bipolar Disorder; Circadian Rhythm; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motor Activity; Quetiapine Fumarate; Sleep; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
Topics: Adult; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Severity of Illness Index; Time Factors; Venlafaxine Hydrochloride | 2007 |
Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Leukoaraiosis; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Nortriptyline; Venlafaxine Hydrochloride | 2007 |
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Pressure; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Statistics as Topic; Venlafaxine Hydrochloride | 2007 |
Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.
Topics: Adolescent; Algorithms; Child; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Placebos; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cross-Over Studies; Cyclohexanols; Decision Trees; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial.
Topics: Adult; Brain; Cerebral Cortex; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Fluorodeoxyglucose F18; Functional Laterality; Glucose; Humans; Limbic System; Male; Middle Aged; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia.
Topics: Aged; Cyclohexanols; Dementia; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Psychomotor Agitation; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2007 |
Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
Topics: Adult; Antidepressive Agents; Citalopram; Corpus Striatum; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline; Venlafaxine Hydrochloride | 2007 |
Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Nortriptyline; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2007 |
Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Related Disorders; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Methylphenidate; Retention, Psychology; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.
Topics: Acute Disease; Adult; Asian People; China; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Prospective Studies; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Outpatients; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lithium Compounds; Male; Middle Aged; Phenelzine; Recurrence; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prevalence; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.
Topics: Aged; Antidepressive Agents; Cholinesterase Inhibitors; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Venlafaxine Hydrochloride | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Arousal; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Libido; Male; Middle Aged; Orgasm; Personality Inventory; Sexual Behavior; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Lithium Compounds; Male; Middle Aged; Patient Dropouts; Psychiatric Status Rating Scales; Psychometrics; Regression Analysis; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Comparison of venlafaxine and imipramine in depressive illness.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Family Practice; Female; Humans; Imipramine; Male; Middle Aged; Patient Care Team; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
[The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine].
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Humans; Paroxetine; Remission, Spontaneous; Severity of Illness Index; Venlafaxine Hydrochloride | 1999 |
Venlafaxine treatment of cocaine abusers with depressive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Cocaine-Related Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Desipramine; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Humans; Male; Middle Aged; Pilot Projects; Treatment Failure; Venlafaxine Hydrochloride | 2000 |
Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.
Topics: Adolescent; Adult; Ambulatory Care; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Personality Inventory; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Fluoxetine; Humans; Immune Tolerance; Lymphocyte Activation; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Venlafaxine Hydrochloride | 2000 |
Venlafaxine monotherapy in women with bipolar II and unipolar major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Retrospective Studies; Sex Factors; Venlafaxine Hydrochloride | 2000 |
Sustained response to open-label venlafaxine in drug-resistant major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Receptors, Serotonin; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Placebo Effect; Venlafaxine Hydrochloride | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Prefrontal Cortex; Single-Blind Method; Venlafaxine Hydrochloride | 2002 |
238 other study(ies) available for venlafaxine hydrochloride and Depression, Involutional
| Article | Year |
|---|---|
Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study.
Topics: Biomarkers; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Topics: Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Cyclohexanols; Depressive Disorder, Major; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tyramine; Venlafaxine Hydrochloride | 2022 |
Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Pharmacists; Pharmacogenetics; Venlafaxine Hydrochloride | 2022 |
Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; ROC Curve; Treatment Outcome; Venlafaxine Hydrochloride | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Mixed lymphocytic and collagenous inflammation of the entire gastrointestinal tract under therapy with serotonin and norepinephrine reuptake inhibitors.
Topics: Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Gastrointestinal Tract; Humans; Inflammation; Middle Aged; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2022 |
Venlafaxine-related galactorrhea in an adolescent female: A case report.
Topics: Adolescent; Amenorrhea; Antidepressive Agents; Depressive Disorder, Major; Female; Galactorrhea; Humans; Hyperprolactinemia; Pregnancy; Venlafaxine Hydrochloride | 2022 |
Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment.
Topics: Aged; Antidepressive Agents; Decision Trees; Depressive Disorder, Major; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2022 |
Electrical stimulus combined with venlafaxine and mirtazapine improves brain Ca
Topics: Animals; Clozapine; Depressive Disorder, Major; Humans; Mice; Mirtazapine; Prefrontal Cortex; Schizophrenia; Venlafaxine Hydrochloride | 2022 |
The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis.
Topics: Adult; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Mirtazapine; Quality of Life; Review Literature as Topic; Venlafaxine Hydrochloride | 2023 |
Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Comorbidity; Depressive Disorder, Major; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2023 |
Optimal dosing of antidepressant drugs.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2019 |
Optimal dosing of antidepressant drugs.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2019 |
Optimal dosing of antidepressant drugs.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2019 |
Venlafaxine ER-related strong suicidal intent in an adult with lithium-treated severe major depression: a phenomenological proximity with other paradoxical reactions of psychoactive agents.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Lithium Compounds; Male; Middle Aged; Psychotropic Drugs; Suicide; Venlafaxine Hydrochloride | 2019 |
A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
Topics: Adult; Alleles; Antidepressive Agents; Asian People; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Mineralocorticoid; Thyrotropin; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
Topics: Adult; Antidepressive Agents; Asian People; Biomarkers, Pharmacological; China; Cytochrome P-450 CYP2C19; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Child; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Fluoxetine; Humans; Liquid-Liquid Extraction; Middle Aged; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Venlafaxine Hydrochloride; Vortioxetine; Young Adult | 2020 |
Apathy symptoms induced by low-dose venlafaxine: Two cases.
Topics: Apathy; Depressive Disorder, Major; Humans; Male; Middle Aged; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2020 |
Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression.
Topics: Adult; Aged; Animals; Cells, Cultured; Cerebral Cortex; Depressive Disorder, Major; Female; Gamma Rhythm; Humans; Male; Matrix Metalloproteinase 9; Memory, Short-Term; Mice; Mice, Inbred C57BL; Middle Aged; Neural Inhibition; Pyramidal Cells; Serotonin and Noradrenaline Reuptake Inhibitors; Stress, Psychological; Venlafaxine Hydrochloride | 2020 |
Pre-pubertal, low-intensity exercise does not require concomitant venlafaxine to induce robust, late-life antidepressant effects in Flinders sensitive line rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; Norepinephrine; Rats; Serotonin; Venlafaxine Hydrochloride | 2020 |
Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: Data from the pride study.
Topics: Aged; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Comparison of venlafaxine alone versus venlafaxine plus late partial sleep deprivation therapy combination for major depressive disorder.
Topics: Circadian Rhythm; Cyclohexanols; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Sleep Deprivation; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Genome-Wide Association Study; Humans; Ion Channels; Male; Multifactorial Inheritance; Venlafaxine Hydrochloride | 2021 |
Dysosmia and drug tolerance with use of venlafaxine.
Topics: Depressive Disorder, Major; Drug Tolerance; Female; Humans; Middle Aged; Olfaction Disorders; Venlafaxine Hydrochloride | 2021 |
Adiponectin predicts poor response to antidepressant drugs in major depressive disorder.
Topics: Adiponectin; Antidepressive Agents; Depressive Disorder, Major; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2021 |
Glutathione conjugation and protein modification resulting from metabolic activation of venlafaxine
Topics: Activation, Metabolic; Animals; Depressive Disorder, Major; Glutathione; Mice; Microsomes, Liver; Rats; Venlafaxine Hydrochloride | 2021 |
Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2017 |
The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Catechol O-Methyltransferase; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2017 |
Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Bupropion; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-17; Male; Mianserin; Middle Aged; Mirtazapine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Severity of Illness Index; T-Lymphocytes; Venlafaxine Hydrochloride | 2017 |
Association between change in brain gray matter volume, cognition, and depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Cognitive Dysfunction; Depressive Disorder, Major; Female; Follow-Up Studies; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Prefrontal Cortex; Severity of Illness Index; Venlafaxine Hydrochloride | 2017 |
Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Case-Control Studies; China; Cytokines; Depression; Depressive Disorder, Major; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Depressive Disorder, Major; Female; France; Genotype; Humans; Male; Middle Aged; Phenotype; Switzerland; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2017 |
Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression?
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nortriptyline; Pain; Pain Measurement; Psychiatric Status Rating Scales; Time Factors; Venlafaxine Hydrochloride | 2018 |
Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.
Topics: Adult; Black People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Gene Frequency; Genotype; Humans; Indians, South American; Male; Polymorphism, Single Nucleotide; Serotonin and Noradrenaline Reuptake Inhibitors; Trinidad and Tobago; Venlafaxine Hydrochloride | 2018 |
Venlafaxine and sertraline does not affect the expression of genes regulating stress response in female MDD patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Middle Aged; Real-Time Polymerase Chain Reaction; Receptors, Glucocorticoid; Sertraline; Severity of Illness Index; Venlafaxine Hydrochloride; Young Adult | 2017 |
How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?
Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Intraocular Pressure; Male; Middle Aged; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2018 |
Seizure Induced by a Therapeutic Dose of Venlafaxine ER: A Case Report.
Topics: Adult; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Seizures; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2018 |
Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Depressive Disorder, Major; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Failure; Venlafaxine Hydrochloride | 2018 |
Bupropion Switch for a Depressed Patient With Venlafaxine-Associated Night Sweats.
Topics: Bupropion; Depressive Disorder, Major; Humans; Hyperhidrosis; Male; Middle Aged; Venlafaxine Hydrochloride | 2018 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Lamotrigine; Mirtazapine; Obsessive-Compulsive Disorder; Serotonin and Noradrenaline Reuptake Inhibitors; Tic Disorders; Venlafaxine Hydrochloride | 2018 |
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2.
Topics: Adult; Aged; Brain; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2019 |
Depression with high levels of anxiety.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder, Major; Humans; Venlafaxine Hydrochloride | 2019 |
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Female; Humans; Irritable Mood; Logistic Models; Male; Middle Aged; Mirtazapine; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.
Topics: Adult; Antidepressive Agents, Second-Generation; Asian People; Depressive Disorder, Major; Female; Gene Frequency; Genetic Association Studies; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, AMPA; Receptors, Kainic Acid; Receptors, Metabotropic Glutamate; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Which antidepressant doses are optimal?
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2019 |
Venlafaxine-related akathisia side-effects and management in a depressed patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Male; Venlafaxine Hydrochloride | 2013 |
Psychomotor depressive symptoms may differentially respond to venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Prospective Studies; Psychomotor Agitation; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Humans; Male; Middle Aged; Risk Factors; Treatment Failure; Venlafaxine Hydrochloride | 2013 |
Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms.
Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.
Topics: Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Drug Interactions; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tremor; Trimethoprim, Sulfamethoxazole Drug Combination; Venlafaxine Hydrochloride | 2013 |
Dose-related paresthesias with venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Paresthesia; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder.
Topics: Adolescent; Adult; Age Factors; Caregivers; Cluster Analysis; Cyclohexanols; Data Mining; Decision Making; Delayed-Action Preparations; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Female; Health Education; Humans; Insurance Claim Reporting; Male; Middle Aged; Observational Studies as Topic; Outcome and Process Assessment, Health Care; Statistics as Topic; Statistics, Nonparametric; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2013 |
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.
Topics: Adolescent; Alkylating Agents; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cyclohexanols; Cyclophosphamide; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Lupus Erythematosus, Systemic; Olanzapine; Prednisolone; Venlafaxine Hydrochloride | 2013 |
Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Asian People; Citalopram; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Serotonin Plasma Membrane Transport Proteins; Single-Blind Method; Time Factors; Venlafaxine Hydrochloride; White People; Young Adult | 2013 |
Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.
Topics: Aged; Bone Resorption; Cyclohexanols; Depressive Disorder, Major; Female; Genetic Variation; Humans; Male; Middle Aged; Osteogenesis; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2014 |
[Antidepressant treatment associated hyponatremia -- case report].
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyclohexanols; Depression; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hyponatremia; Male; Mianserin; Mirtazapine; Recurrence; Severity of Illness Index; Sodium; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
When depression doesn't lead with depression.
Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fluoxetine; Humans; Irritable Mood; Male; Mood Disorders; Prefrontal Cortex; Venlafaxine Hydrochloride | 2013 |
High impact child abuse may predict risk of elevated suicidality during antidepressant initiation.
Topics: Adult; Adult Survivors of Child Abuse; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Risk Factors; Suicidal Ideation; Suicide, Attempted; Venlafaxine Hydrochloride | 2013 |
Acute bilateral parotitis occurring during venlafaxine titration in an adolescent female with major depression.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Parotitis; Pregnancy; Venlafaxine Hydrochloride; Young Adult | 2014 |
Case report of a 24-year-old man with resolution of treatment-resistant major depressive disorder and comorbid PTSD using rTMS.
Topics: Antidepressive Agents, Second-Generation; Combat Disorders; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diagnostic and Statistical Manual of Mental Disorders; Humans; Male; Military Personnel; Stress Disorders, Post-Traumatic; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride; Young Adult | 2014 |
Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Catechol O-Methyltransferase; Cyclohexanols; Depressive Disorder, Major; Epistasis, Genetic; Female; Humans; Male; Middle Aged; Paroxetine; Receptors, Dopamine D2; Republic of Korea; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
An observational study of Venlafaxine and CYP2D6 in clinical practice.
Topics: Adult; Aged; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Phenotype; Practice Patterns, Physicians'; Venlafaxine Hydrochloride | 2014 |
Long-standing depression and anxiety in a Korean woman.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Republic of Korea; Venlafaxine Hydrochloride | 2014 |
Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Humans; Male; Middle Aged; Venlafaxine Hydrochloride | 2015 |
Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Synergism; Drug Therapy, Combination; Female; Health Care Costs; Humans; Isoenzymes; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2014 |
The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Disease Management; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain; Pain Measurement; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2014 |
SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
Topics: Adult; Asian People; Cyclohexanols; Depressive Disorder, Major; Female; Genetic Testing; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Single Nucleotide; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Differential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control Studies; Cyclohexanols; Depression; Depressive Disorder, Major; Female; Gene Regulatory Networks; Humans; Leukocytes, Mononuclear; Male; Microarray Analysis; Venlafaxine Hydrochloride | 2015 |
[Venlafaxine in the treatment of moderate and severe depressions: the ways to increase treatment efficacy].
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
Topics: Adult; Affect; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2016 |
Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Flow Cytometry; Humans; Imipramine; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2015 |
Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Antidepressive Agents; Attention; Cognition Disorders; Depressive Disorder, Major; Diagnosis, Differential; Drug Therapy, Combination; Essential Tremor; Fluorodeoxyglucose F18; Glucose Metabolism Disorders; Humans; Lithium Compounds; Male; Memory Disorders; Memory, Episodic; Mental Recall; Neuropsychological Tests; Positron-Emission Tomography; Primidone; Radiopharmaceuticals; Recurrence; Venlafaxine Hydrochloride | 2015 |
Venlafaxine induced QTc interval prolongation in a therapeutic dose.
Topics: Adult; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Long QT Syndrome; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2015 |
Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.
Topics: Aged; Antidepressive Agents; Bayes Theorem; Depressive Disorder, Major; Disease Progression; Female; Guilt; Humans; Linear Models; Male; Middle Aged; Prognosis; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Decision Trees; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Markov Chains; Piperazines; Quality-Adjusted Life Years; Recurrence; Republic of Korea; Sulfides; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2016 |
A case of venlafaxine-induced kleptomania.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Middle Aged; Venlafaxine Hydrochloride | 2016 |
A Woman With Major Depression With Psychotic Features Requesting a Termination of Pregnancy.
Topics: Abortion Applicants; Adult; Benzodiazepines; Depressive Disorder, Major; Drug Dosage Calculations; Female; Humans; Olanzapine; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Psychiatric Status Rating Scales; Psychological Techniques; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
[Cognitive dysfunction in major depression].
Topics: Attention; Cognition Disorders; Depressive Disorder, Major; Drug Therapy, Combination; Executive Function; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Rehabilitation, Vocational; Stress, Psychological; Venlafaxine Hydrochloride | 2015 |
Critical Slowing Down as a Personalized Early Warning Signal for Depression.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Models, Psychological; Time Factors; Venlafaxine Hydrochloride | 2016 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; Cohort Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nortriptyline; Pramipexole; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine; Young Adult | 2016 |
Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist: Is Venlafaxine XR Effective for Major Depression in People with Spinal Cord Injury?
Topics: Depressive Disorder, Major; Double-Blind Method; Humans; Peer Review; Physiatrists; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Treatment Emergent Suicidal Ideation in depressed older adults.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Incidence; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Serotonin and Noradrenaline Reuptake Inhibitors; Suicidal Ideation; Venlafaxine Hydrochloride | 2017 |
Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Executive Function; Female; Humans; Male; Neuropsychological Tests; Reaction Time; Venlafaxine Hydrochloride | 2016 |
Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Statistics, Nonparametric; Trail Making Test; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Celery root extract as an inducer of mania induction in a patient on venlafaxine and St John's Wort.
Topics: Antidepressive Agents, Second-Generation; Apium; Bipolar Disorder; Depressive Disorder, Major; Female; Herb-Drug Interactions; Humans; Hypericum; Menopause; Middle Aged; Phytotherapy; Plant Preparations; Plant Roots; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2016 |
Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Geriatric Assessment; Humans; Male; Missouri; Pennsylvania; Self Report; Sleep Apnea, Obstructive; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Topics: Acetamides; Antidepressive Agents; Bupropion; Cost-Benefit Analysis; Decision Trees; Depressive Disorder, Major; Finland; Humans; Markov Chains; Models, Theoretical; Piperazines; Recurrence; Sertraline; Sulfides; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2017 |
Usefulness of repetitive transcranial magnetic stimulation as a maintenance treatment in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride | 2018 |
Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
Topics: Aged; Depressive Disorder, Major; Female; Gene Expression Profiling; Genetic Markers; Genotype; Humans; Likelihood Functions; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Psychometrics; Quantitative Trait Loci; Treatment Outcome; Venlafaxine Hydrochloride | 2017 |
Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.
Topics: Adult; Aged; Akathisia, Drug-Induced; ATP Binding Cassette Transporter, Subfamily B; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2017 |
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Bupropion; Citalopram; Cluster Analysis; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Randomized Controlled Trials as Topic; Sleep; Syndrome; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2017 |
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Databases, Factual; Depressive Disorder, Major; Drug Costs; Drug Utilization; Female; Health Care Costs; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; England; Female; Hospital Costs; Humans; Length of Stay; Male; Middle Aged; Referral and Consultation; Retrospective Studies; Venlafaxine Hydrochloride | 2008 |
Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions?
Topics: Cyclohexanols; Depressive Disorder, Major; Humans; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2008 |
Identifying patients at risk of complete nonresponse in the outpatient treatment of depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Data Interpretation, Statistical; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Resistance; Female; Humans; Male; Middle Aged; Nortriptyline; Psychotherapy; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Severity of Illness Index; Venlafaxine Hydrochloride; Young Adult | 2008 |
[The place of escitalopram in the severe depressive episodes].
Topics: Age Factors; Citalopram; Cyclohexanols; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
[A place for SSRIs in the treatment of severely depressed children and adolescents].
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Venlafaxine Hydrochloride | 2008 |
[Hypomania/mania induced by cessation of antidepressant drugs].
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2008 |
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Mianserin; Middle Aged; Mirtazapine; Venlafaxine Hydrochloride | 2008 |
[Combining venlafaxine and mirtazapine for the treatment of major depression with dysthymia--"double depression"].
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Dysthymic Disorder; Female; Humans; Mianserin; Mirtazapine; Venlafaxine Hydrochloride | 2008 |
The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Economics, Pharmaceutical; Fluoxetine; Focus Groups; Humans; Models, Theoretical; Psychometrics; Selective Serotonin Reuptake Inhibitors; Thailand; Venlafaxine Hydrochloride | 2008 |
Venlafaxine-induced excessive yawning.
Topics: Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Yawning; Young Adult | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Taurine transporter in lymphocytes of patients with major depression treated with venlafaxine plus psychotherapy.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cyclohexanols; Depressive Disorder, Major; Humans; Interleukin-2; Interleukin-4; Lymphocytes; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Venlafaxine Hydrochloride | 2009 |
Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
Topics: Adolescent; Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Male; Middle Aged; Observer Variation; Personality Inventory; Psychometrics; Pyridines; Reproducibility of Results; Somatoform Disorders; Taiwan; Venlafaxine Hydrochloride; Young Adult; Zolpidem | 2009 |
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cyclohexanols; Decision Trees; Delphi Technique; Depressive Disorder, Major; Drug Costs; Drugs, Generic; Fluoxetine; Humans; Psychiatric Status Rating Scales; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom; Venlafaxine Hydrochloride | 2009 |
Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone.
Topics: Adult; Antidepressive Agents, Second-Generation; Buspirone; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Severity of Illness Index; Sleep Bruxism; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Olanzapine; Personality Inventory; Psychometrics; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Major depression, antidepressant medication and the risk of obesity.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Incidence; Male; Middle Aged; Obesity; Risk Factors; Venlafaxine Hydrochloride; Young Adult | 2009 |
Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Denmark; Depressive Disorder, Major; Dothiepin; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Venlafaxine-induced complex visual hallucinations in a 17-year-old boy.
Topics: Adolescent; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Hallucinations; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Antidepressant switching among adherent patients treated for depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug Administration Schedule; Humans; Mianserin; Middle Aged; Mirtazapine; Patient Compliance; Sertraline; Trazodone; Venlafaxine Hydrochloride; Young Adult | 2009 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropion; Child; Child Abuse, Sexual; Chronic Disease; Citalopram; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Life Change Events; Male; Mianserin; Middle Aged; Mirtazapine; Parenting; Risk Factors; Self Concept; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Regarding "Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs".
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine.
Topics: Adult; Clomipramine; Cyclohexanols; Delusions; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2009 |
Venlafaxine versus SSRI therapy for major depression. Results of comparative efficacy trials.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Antidepressive Agents; Climacteric; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Morpholines; Personality Inventory; Reboxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride; Young Adult | 2009 |
Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Drug Resistance; Female; Humans; Lithium; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
Cortisol metabolism in depressed patients and healthy controls.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cortisone; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Hydrocortisone; Mianserin; Middle Aged; Mirtazapine; Tetrahydrocortisol; Tetrahydrocortisone; Venlafaxine Hydrochloride; Young Adult | 2009 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Longitudinal changes of day-time and night-time gross motor activity in clinical responders and non-responders of major depression.
Topics: Actigraphy; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Circadian Rhythm; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Middle Aged; Motor Activity; Personality Inventory; Prognosis; Prospective Studies; Quetiapine Fumarate; Signal Processing, Computer-Assisted; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Neurotrophic factors in serum following ECT: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Nerve Growth Factors; Pilot Projects; Psychotherapy; Psychotropic Drugs; Recurrence; Reference Values; Venlafaxine Hydrochloride | 2009 |
Pro-inflammatory biomakers in depression: treatment with venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Inflammation Mediators; Male; Middle Aged; Personality Inventory; Reference Values; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Combining antidepressant medications: a good idea?
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Humans; Mianserin; Mirtazapine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2010 |
Management of depression in the presence of pain symptoms.
Topics: Antidepressive Agents; Brain; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Fibromyalgia; Humans; Milnacipran; Mind-Body Relations, Metaphysical; Norepinephrine; Pain; Psychotherapy; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
Topics: Antidepressive Agents, Second-Generation; Biotransformation; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Humans; Mental Disorders; Metabolic Clearance Rate; Pharmacogenetics; Phenotype; Psychotropic Drugs; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Venlafaxine - quetiapine combination in the treatment of complicated clinical picture of enduring personality changes following PTSD in comorbidity with psychotic depression.
Topics: Affective Disorders, Psychotic; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Combat Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Personality Disorders; Quetiapine Fumarate; Secondary Prevention; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride; Veterans | 2010 |
Treatment of psychotic depression in the elderly compared with nonpsychotic depression.
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; Depressive Disorder, Major; Follow-Up Studies; Humans; Middle Aged; Nortriptyline; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2010 |
Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
Topics: Adult; Alleles; Asian People; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2010 |
Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Markov Chains; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sweden; Thiophenes; Venlafaxine Hydrochloride | 2010 |
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Fluoxetine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2011 |
The bipolar spectrum: do we need a single algorithm for affective disorders?
Topics: Algorithms; Antidepressive Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Humans; Practice Guidelines as Topic; Primary Health Care; Referral and Consultation; Risk Factors; Venlafaxine Hydrochloride | 2010 |
Gambling on acamprosate: a case report.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Second-Generation; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Gambling; Humans; Middle Aged; Taurine; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Drug Combinations; Drug Costs; Female; Health Care Costs; Health Resources; Humans; Male; Retrospective Studies; Spain; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
A case of venlafaxine-induced bruxism alleviated by duloxetine substitution.
Topics: Aged; Antidepressive Agents; Bruxism; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Female; Health Care Costs; Humans; Male; Middle Aged; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Paliperidone augmentation for treatment-resistant depression: a case report.
Topics: Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Pyrimidines; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Venlafaxine pharmacobezoar causing intestinal ischemia requiring emergent hemicolectomy.
Topics: Abdominal Pain; Adult; Bezoars; Colectomy; Cyclohexanols; Depressive Disorder, Major; Edema; Emergency Medical Services; Female; Humans; Ileocecal Valve; Intestinal Obstruction; Laparotomy; Necrosis; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Tachycardia; Venlafaxine Hydrochloride | 2011 |
Venlafaxine withdrawal syndrome.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Ischemic Attack, Transient; Retreatment; Stroke; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2011 |
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Topics: Adolescent; Adult; Algorithms; Antidepressive Agents; Chronic Disease; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dosage Forms; Duloxetine Hydrochloride; Female; Humans; Male; Medication Adherence; Middle Aged; Pain; Retrospective Studies; Somatoform Disorders; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2011 |
Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; CREB-Binding Protein; Cyclohexanols; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Hydrocortisone; Lymphocytes; Male; Middle Aged; Pilot Projects; Receptors, Glucocorticoid; Time Factors; Venlafaxine Hydrochloride | 2011 |
Electroconvulsive therapy in older adults.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Retreatment; Venlafaxine Hydrochloride | 2011 |
Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Chronic Disease; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Inpatients; Israel; Male; Medical Records Systems, Computerized; Middle Aged; Psychiatric Status Rating Scales; Receptors, Adrenergic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Cyclohexanols; Data Interpretation, Statistical; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Hyponatremia; Male; Mianserin; Middle Aged; Mirtazapine; Republic of Korea; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sodium; Venlafaxine Hydrochloride; Young Adult | 2011 |
Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Inflammation; Inflammation Mediators; Interleukin-1; Interleukin-6; Male; Middle Aged; Neuropeptide Y; Severity of Illness Index; Tumor Necrosis Factor-alpha; Up-Regulation; Venlafaxine Hydrochloride | 2012 |
Venlafaxin-associated post-ictal asystole during electroconvulsive therapy.
Topics: Aged, 80 and over; Bipolar Disorder; Contraindications; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Heart Arrest; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Questions raised by the failure of a trial of short-term psychodynamic therapy versus pharmacotherapy for major depressive disorder.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Approval; Female; Humans; Male; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Sertraline; United States Food and Drug Administration; Venlafaxine Hydrochloride | 2012 |
Optimized light therapy for non-seasonal major depressive disorder: effects of timing and season.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Phototherapy; Seasons; Time Factors; Venlafaxine Hydrochloride | 2012 |
Saving lives: can we predict and prevent adolescent suicide?
Topics: Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Joy returns last: anhedonia and treatment resistance in depressed adolescents.
Topics: Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Fatal agranulocytosis associated with psychotropic medication use.
Topics: Adult; Agranulocytosis; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Blood Cell Count; Cyclohexanols; Depressive Disorder, Major; Dibenzothiazepines; Fatal Outcome; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lamotrigine; Mianserin; Mirtazapine; Multiple Organ Failure; Neutropenia; Orbital Cellulitis; Psychotic Disorders; Psychotropic Drugs; Quetiapine Fumarate; Recombinant Proteins; Shock, Septic; Triazines; Venlafaxine Hydrochloride | 2012 |
5-HT2A receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study.
Topics: Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Humans; Male; Middle Aged; Prospective Studies; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Venlafaxine Hydrochloride; Young Adult | 2012 |
Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Corticotropin-Releasing Hormone; Cyclohexanols; Depressive Disorder, Major; Female; Glutamic Acid; Glutamine; Humans; Male; Middle Aged; Suicidal Ideation; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.
Topics: Adult; Aged; Antidepressive Agents; Australia; Bayes Theorem; Cyclohexanols; Databases, Factual; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Nausea; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Topics: Adult; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Models, Economic; Quality of Life; Sertraline; Thailand; Venlafaxine Hydrochloride | 2012 |
The challenge of treating (and supervising) patients with borderline pathology in a residents' clinic.
Topics: Adult; Antidepressive Agents, Second-Generation; Borderline Personality Disorder; Countertransference; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Internship and Residency; Prescription Drug Misuse; Psychiatry; Psychotherapy; Pyridines; Self-Injurious Behavior; Transference, Psychology; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult; Zolpidem | 2012 |
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Humans; Intention; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Personality Inventory; Primary Health Care; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Sertraline; Suicidal Ideation; Suicide, Attempted; Thinking; Venlafaxine Hydrochloride | 2012 |
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Genotype; Heterozygote; Humans; Male; Polymorphism, Single Nucleotide; Predictive Value of Tests; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2012 |
A case of high-dose venlafaxine-related psychosis.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Male; Middle Aged; Psychoses, Substance-Induced; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Australia; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Humans; Hypericum; Markov Chains; Middle Aged; Models, Economic; Phytotherapy; Plant Preparations; Sertraline; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Treatment of posttraumatic stress disorder with tiagabine.
Topics: Adult; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; Nipecotic Acids; Stress Disorders, Post-Traumatic; Tiagabine; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
The brain tells: early signs of depression recovery.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Prefrontal Cortex; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Venlafaxine Hydrochloride | 2002 |
The neural substrates of affective processing in depressed patients treated with venlafaxine.
Topics: Adult; Affect; Amygdala; Brain Mapping; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up Studies; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
Gabapentin and posttraumatic stress disorder.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids; Cyclohexanols; Depressive Disorder, Major; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2003 |
Combined oral venlafaxine and intravenous clomipramine-A: successful temporary response in a patient with extremely refractory depression.
Topics: Administration, Oral; Adult; Clomipramine; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2004 |
Venlafaxine withdrawal syndrome: report of seven cases in Trinidad.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Male; Middle Aged; Substance Withdrawal Syndrome; Trinidad and Tobago; Venlafaxine Hydrochloride | 2004 |
Elevated defibrillation threshold with venlafaxine therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Defibrillators, Implantable; Depressive Disorder, Major; Equipment Failure; Female; Heart Arrest; Humans; Venlafaxine Hydrochloride | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Buspirone to improve compliance in venlafaxine-induced movement disorder.
Topics: Antidepressive Agents, Second-Generation; Buspirone; Compliance; Cyclohexanols; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Serotonin Receptor Agonists; Venlafaxine Hydrochloride | 2004 |
[Depression in Hashimoto's encephalopathy. Successful treatment of a severe depressive episode with a glucocorticoid as an add-on therapy].
Topics: Aged; Chemotherapy, Adjuvant; Cyclohexanols; Depressive Disorder, Major; Drug Combinations; Female; Glucocorticoids; Humans; Prednisolone; Severity of Illness Index; Thyroiditis, Autoimmune; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
A possible case of venlafaxine-induced Stevens-Johnson syndrome.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Exanthema; Female; Humans; Methylprednisolone; Selective Serotonin Reuptake Inhibitors; Stevens-Johnson Syndrome; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Medication-associated somnambulism.
Topics: Adolescent; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Pyridines; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Somnambulism; Venlafaxine Hydrochloride; Zolpidem | 2005 |
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Topics: Antidepressive Agents, Second-Generation; Belgium; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Costs; Humans; Models, Economic; Practice Patterns, Physicians'; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Relationship of white matter hyperintensities to cerebrospinal fluid glucose polyol pathway metabolites-a pilot study in treatment-resistant affective disorder patients.
Topics: Adult; Aged; Bipolar Disorder; Blood Glucose; Brain; Brain Diseases, Metabolic; Cyclohexanols; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Drug Resistance; Female; Glucans; Humans; Image Enhancement; Image Processing, Computer-Assisted; Lithium Carbonate; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Psychotic Disorders; Psychotropic Drugs; Reference Values; Risk Factors; Sorbitol; Statistics as Topic; Venlafaxine Hydrochloride | 2005 |
Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Epistaxis; Gastrointestinal Hemorrhage; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2005 |
Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine.
Topics: Adult; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Narcolepsy; Polysomnography; Substance Withdrawal Syndrome; Treatment Failure; Venlafaxine Hydrochloride | 2005 |
Adolescents' response to antidepressant treatment in a community mental health center.
Topics: Adolescent; Adolescent Psychiatry; Algorithms; Antidepressive Agents; Child; Child Psychiatry; Citalopram; Community Mental Health Centers; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Male; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Multimodal therapy of treatment resistant depression: a study and analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Culture; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Humans; Self Concept; Severity of Illness Index; Venlafaxine Hydrochloride | 2005 |
Olanzapine plus venlafaxine in treatment-resistant depression.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Humans; Olanzapine; Venlafaxine Hydrochloride | 2005 |
Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sex Factors; Time Factors; Venlafaxine Hydrochloride | 2005 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Venlafaxine and asthma.
Topics: Asthma; Cyclohexanols; Depressive Disorder, Major; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2005 |
Venlafaxine and the rapid development of anasarca.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Edema; Female; Humans; Vasomotor System; Venlafaxine Hydrochloride | 2006 |
Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient.
Topics: Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Serotonin Syndrome; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2006 |
Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2005 |
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Creatinine; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Venlafaxine Hydrochloride | 2006 |
[Love, humor and psychosis in an atypical depression].
Topics: Antidepressive Agents; Antipsychotic Agents; Azabicyclo Compounds; Benzodiazepines; Clonazepam; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; Love; Olanzapine; Piperazines; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Wit and Humor as Topic | 2005 |
Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2006 |
Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder.
Topics: Aged; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimulants; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperkinesis; Modafinil; Neurologic Examination; Venlafaxine Hydrochloride | 2006 |
Lithium and venlafaxine interaction: a case of serotonin syndrome.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Female; Humans; Lithium Carbonate; Serotonin Syndrome; Venlafaxine Hydrochloride | 2006 |
Is it possible to predict the long-term response to venlafaxine with the use of biological markers and psychophysiological methods?
Topics: Adult; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanols; Depressive Disorder, Major; Dexamethasone; Dexfenfluramine; Dominance, Cerebral; Electrooculography; Electroretinography; Evoked Potentials, Visual; Female; Follow-Up Studies; Globus Pallidus; Humans; Hydrocortisone; Male; Middle Aged; Prognosis; Prolactin; Recurrence; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Topiramate use in alprazolam addiction.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Female; Fructose; Humans; Substance Withdrawal Syndrome; Substance-Related Disorders; Topiramate; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Databases as Topic; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Regression Analysis; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Emotions; Female; Fluoxetine; Frontal Lobe; Gyrus Cinguli; Humans; Male; Mental Recall; Middle Aged; Paired-Associate Learning; Personality Inventory; Positron-Emission Tomography; Semantics; Sertraline; Venlafaxine Hydrochloride; Wechsler Scales | 2007 |
STAR*D: what have we learned?
Topics: Ambulatory Care; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Follow-Up Studies; Humans; Lithium Compounds; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Tranylcypromine; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.
Topics: Acetamides; Adult; Anti-Infective Agents; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Female; Humans; Linezolid; Monoamine Oxidase Inhibitors; Oxazolidinones; Serotonin Syndrome; Venlafaxine Hydrochloride | 2007 |
Venlafaxine for major depression.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Humans; Venlafaxine Hydrochloride | 2007 |
Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis.
Topics: Adult; Affect; Biogenic Monoamines; Brain Stem; Caudate Nucleus; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Disruptive, Impulse Control, and Conduct Disorders; Female; Fluorodeoxyglucose F18; Fluoxetine; Gyrus Cinguli; Hippocampus; Humans; Hypothalamus; Magnetic Resonance Imaging; Male; Nucleus Accumbens; Positron-Emission Tomography; Psychomotor Disorders; Putamen; Radiopharmaceuticals; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2007 |
Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Female; Haloperidol; Humans; Lewy Body Disease; Neostriatum; Parkinson Disease, Secondary; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes; Venlafaxine Hydrochloride | 2007 |
Antidepressant response in the elderly.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Data safety monitoring boards and other study methodologies that address subject safety in "high-risk" therapeutic trials in youths.
Topics: Adolescent; Child; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Human Experimentation; Humans; Male; Research Design; Risk Factors; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Denmark; Depressive Disorder, Major; Drug Costs; Humans; Models, Economic; Practice Patterns, Physicians'; Primary Health Care; Remission Induction; Venlafaxine Hydrochloride | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Non-pharmacological treatment of psychiatrists in addition to the prescribing of an antidepressant drug.
Topics: Antidepressive Agents, Second-Generation; Combined Modality Therapy; Counseling; Cyclohexanols; Depressive Disorder, Major; Drug Prescriptions; Female; Humans; Male; Middle Aged; Physicians; Psychiatry; Psychotherapy; Sex Factors; Venlafaxine Hydrochloride | 2007 |
Using psychostimulants for treating residual symptoms in major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimulants; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Modafinil; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2007 |
Photodistributed eruptive telangiectasia: an uncommon adverse drug reaction to venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Eruptions; Female; Humans; Middle Aged; Photosensitivity Disorders; Selective Serotonin Reuptake Inhibitors; Telangiectasis; Venlafaxine Hydrochloride | 2007 |
Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Depressive Disorder, Major; Dysthymic Disorder; Female; Genotype; Humans; Male; Middle Aged; Retrospective Studies; Treatment Failure; Venlafaxine Hydrochloride | 2007 |
Venlafaxine-lithium toxicity: suitability for use in the elderly.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Female; Humans; Lithium Compounds; Risk; Serotonin Syndrome; Venlafaxine Hydrochloride | 2007 |
Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Topics: Adrenergic Uptake Inhibitors; Adult; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Neurotransmitter Uptake Inhibitors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Thiophenes; Venlafaxine Hydrochloride | 2008 |
Sertraline versus venlafaxine XR in major depressive disorder.
Topics: Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2007 |
Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Hypotension; Polymorphism, Genetic; Receptors, Adrenergic, alpha-2; Venlafaxine Hydrochloride | 2008 |
Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
Topics: Adult; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Fluoxetine; Hospitalization; Humans; Interview, Psychological; Male; Mood Disorders; Patient Readmission; Prevalence; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Time Factors; Tobacco Use Disorder; Venlafaxine Hydrochloride | 2008 |
A case of extreme paradoxical insomnia responding selectively to electroconvulsive therapy.
Topics: Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Dibenzothiazepines; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Humans; Middle Aged; Quetiapine Fumarate; Sick Role; Sleep Initiation and Maintenance Disorders; Suicide; Suicide Prevention; Venlafaxine Hydrochloride | 2008 |
Similar effects of tramadol and venlafaxine in major depressive disorder.
Topics: Adult; Analgesics, Opioid; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Low Back Pain; Selective Serotonin Reuptake Inhibitors; Tramadol; Venlafaxine Hydrochloride | 2008 |
Asystole during electroconvulsive therapy in an elderly woman treated concomitantly with venlafaxine.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Heart Arrest; Humans; Venlafaxine Hydrochloride | 2008 |
Venlafaxine: Successful treatment in impulsive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Compulsive Behavior; Cyclohexanols; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Venlafaxine Hydrochloride | 2008 |
Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.
Topics: Adolescent; Adult; Cyclohexanols; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Middle Aged; Personality Disorders; Predictive Value of Tests; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Theta Rhythm; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The review by Weinmann and colleagues.
Topics: Antidepressive Agents, Second-Generation; Bias; Cyclohexanols; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Mood Disorders; Risk Factors; Venlafaxine Hydrochloride | 1997 |
Use of bupropion with SRIs and venlafaxine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Assessment; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Lithium augmentation of venlafaxine in adolescent major depression.
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Lithium Carbonate; Male; Psychotherapy; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.
Topics: Aged; Antidepressive Agents, Second-Generation; Coronary Circulation; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Electrocardiography; Female; Humans; Myocardial Infarction; Norepinephrine; Platelet Aggregation; Serotonin; Venlafaxine Hydrochloride | 1999 |
Abnormal clotting and production of factor VIII inhibitor in a patient treated with venlafaxine.
Topics: Blood Coagulation Disorders; Cyclohexanols; Depressive Disorder, Major; Factor VIII; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Biopsy; Cyclohexanols; Depressive Disorder, Major; Humans; Lung; Male; Prednisone; Pulmonary Eosinophilia; Respiratory Insufficiency; Tomography, X-Ray Computed; Venlafaxine Hydrochloride | 2000 |
Defense mechanisms and personality in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Defense Mechanisms; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Patient Dropouts; Personality Disorders; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Critical use of venlafaxine serology to uncover genetic rapid metabolism.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Metabolic Clearance Rate; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Lithium augmentation in venlafaxine-refractory depression.
Topics: Antimanic Agents; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Lithium Chloride; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride | 2001 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression.
Topics: Aged; Anesthetics, Intravenous; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Electroconvulsive Therapy; Female; Heart Arrest; Heart Rate; Humans; Male; Middle Aged; Propofol; Retrospective Studies; Sodium Channels; Venlafaxine Hydrochloride | 2002 |
Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression.
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retrospective Studies; Venlafaxine Hydrochloride | 2002 |